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Introduction
In the middle of the nineteenth century Rudolf 
Virchow described for the first time neuroglia 
as a connective tissue that glued nervous 
elements together [1]. Later studies of Camillo 
Golgi allowed to recognise the cellular nature 
of glia [2,3], then identified as a group of 
cells distinguishable from neurons. Central 
nervous system (CNS) glial cells encompass 
oligodendrocytes, the myelin forming cells, 
microglial cells, the brain/spinal cord resident 
macrophages, and astrocytes that are the 
most numerous component and account for 
a large portion of total brain volume (20-50%). 
Their name was coined in 1891 by Michael von 
Lenhossek who called “astrocytes” the star-
shaped cells found in the CNS. Once considered 
only passive scaffolds for neurons, in the last two 
decades astrocytes have been shown to play 
multiple roles in brain physiology thanks to the 
development of new technologies to study their 
in vivo function. Astrocytes are also emerging as 
important contributors to the pathogenesis of a 
variety of neurological diseases.
Astrocytes are distributed throughout 
the CNS, in the grey and white matter. Two 
morphologically distinct astrocyte populations 
can be found. The protoplasmic astrocytes of the 
grey matter exhibit many branches uniformly 
distributed around the cell body, each of which 
gives rise to finely branching processes. The 
fibrous astrocytes are mainly localised along 
myelinated fiber tracts in the white matter and are 
characterized by many long fiber-like processes 
[4,5]. The intermediate filament glial fibrillary 
acid protein (GFAP) is the specific astrocyte 
marker, even though the variability of the GFAP 
expression in mature astrocytes in healthy CNS 
can limit its in vivo use [6,7]. The dense network 
of specialized, finely branched processes 
extending from the cell body allows astrocytes 
to contact and ensheath cerebral blood vessels 
and neuronal synapses whose development and 
functionality are strictly regulated by astrocytes. 
Due to their strategic location and structural 
and biochemical features astrocytes are the 
cells optimized by the natural selection to sense 
and dynamically respond to changes in the CNS 
microenvironment. By means of functionally 
specialized molecular settings at astrocyte-
neuron contacts astrocytes deliver energy 
substrates to neurons and regulate their activity 
by controlling neurotransmitter metabolism 
and, more in general, the homeostasis of 
synaptic transmission. Astrocyte endfeet also 
project toward blood vessels participating in the 
formation and maintenance of the blood-brain 
barrier (BBB) where they regulate water and 
solute exchange between the blood circulation 
and the neural milieu. Astrocytes also contact 
the pial membrane and the ependymal layer 
lining the ventricles, thus representing the main 
neural cell type interfacing with the external 
environment. Moreover, via specific intercellular 
communication structures, the gap junctions, 
astrocytes are structurally and functionally 
interconnected in a highly organized network 
allowing them to coordinate their activities like 
a cell syncytium, by transfer of small molecules 
like ions and second messengers. Through 
gap junction communication, astrocytes can 
also modulate the activity of adjacent cells, 
like oligodendrocytes and neurons, over long 
distances.
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Abstract
Astrocytes are the predominant glial cell population in the central nervous system (CNS). Once considered only 
passive scaffolding elements, astrocytes are now recognised as cells playing essential roles in CNS development 
and function. They control extracellular water and ion homeostasis, provide substrates for energy metabolism, and 
regulate neurogenesis, myelination and synaptic transmission. Due to these multiple activities astrocytes have 
been implicated in almost all brain pathologies, contributing to various aspects of disease initiation, progression 
and resolution. Evidence is emerging that astrocyte dysfunction can be the direct cause of neurodegeneration, 
as shown in Alexander’s disease where myelin degeneration is caused by mutations in the gene encoding the 
astrocyte-specific cytoskeleton protein glial fibrillary acidic protein. Recent studies point to a primary role for 
astrocytes in the pathogenesis of other genetic leukodystrophies such as megalencephalic leukoencephalopathy 
with subcortical cysts and vanishing white matter disease. The aim of this review is to summarize current 
knowledge of the pathophysiological role of astrocytes focusing on their contribution to the development of 
the above mentioned leukodystrophies and on new perspectives for the treatment of neurological disorders.
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Considering their key role in maintaining 
tissue homeostasis, astrocytes not only carry 
out essential functions in the healthy CNS but 
are also involved in virtually all pathological 
processes. Astrocytes respond to a variety of 
pathological insults by activating complex 
biochemical processes and by undergoing 
morphological changes, collectively called 
“reactive astrogliosis”, which can eventually 
lead to cell proliferation and scar formation. 
Moreover, astrocytes contribute to the brain 
defence response through their antioxidant 
and immunomodulatory activities. There 
is increasing evidence that alterations in 
astrocyte functionality play a crucial role in 
neurodegenerative diseases, inflammatory 
demyelinating diseases, infections, metabolic 
diseases, intoxication, leukodystrophies, 
epilepsy, migraine and schizophrenia (reviewed 
by [7]). Of major interest is the involvement of 
astrocytes in the pathological events leading 
to myelin disturbance.   Although already 
hypothesized in the past, this possibility has 
been recently confirmed by the identification of 
disorders in which myelin degeneration occurs 
as a consequence of a primary astrocyte defect. 
Alexander’s disease (AxD), a leukodystrophy 
caused by mutations in the GFAP gene, is 
the prototypic disease, but recently new 
clinical entities, particularly among genetic 
leukodystrophies, like megalencephalic 
leukoencephalopathy with subcortical cysts 
(MLC) and childhood ataxia with central 
hypomyelination (CACH)/vanishing white 
matter disease (VWM), have been added to this 
group.
In this review we summarize general 
astrocyte functions in the healthy CNS and 
provide some examples of neurological diseases 
whose pathogenic mechanisms directly alter 
astrocyte physiology. We will then discuss in 
more detail the genetic leukodystrophies in 
which a primary pathogenic role for astrocytes 
has been described and the possibility to target 
these cells for therapeutic intervention. 
Astrocytes in CNS physiology 
Evidence accumulated over the last 20 years has 
revealed that astrocytes are mainly devoted to 
the maintenance of CNS homeostasis at several 
levels. At the molecular level they continuously 
check the entire CNS by regulating the 
concentration and exchange of ions, water, 
neurotransmitters, neurohormones, and 
energy and metabolic substrates. Moreover, 
astrocytes control cellular and organ 
homeostasis, being involved in neurogenesis 
and synaptogenesis and in the formation and 
maintenance of the BBB. These fundamental 
activities are directly related to specialized 
plasmamembrane domains that are distributed 
along astrocyte processes in a polarized 
manner and are equipped with specific 
proteins and macromolecular complexes, 
enabling astrocytes to exert different functions 
depending on the environmental context. 
Although astrocyte plasmamembrane domains 
are functionally linked among them, for clarity 
reasons in the next sections we shall discuss 
separately the molecular organization and 
intercellular interactions and activities of each 
astrocytic functional domain.
Astrocytes and neurons: the 
synaptic domain (Figure 1) 
Astrocyte-neuron relationships start during 
development when astrocytes regulate 
neurogenesis by guiding and supporting 
neuronal migration, survival and process 
extension [8]. Astrocytes participate in the 
formation, maintenance and remodelling of 
synapses mainly through release of trophic 
factors such as brain-derived neurotrophic factor 
Figure 1.  Astrocyte-neuron relationships. Astrocytes are involved in the uptake and release of neurotransmitters, 
trophic factors and energy substrates for neurons and in the control of ion homeostasis. Astrocytes 
respond with Ca2+ elevations to neurotransmitters released during synaptic activity and, in turn, control 
neuronal excitability and synaptic transmission through the Ca2+-dependent release of gliotransmitters 
such as glutamate, ATP, GABA and D-serine. The uptake of the neurotransmitter glutamate from the 
synaptic cleft by astrocytes occurs via Na+-dependent excitatory amino acid transporters (EAATs). 
Glutamate is then converted into glutamine by glutamine synthetase (GS) and released back to neurons 
where it is converted to glutamate by glutaminase. Na+, K+-ATPase provides the Na+-mediated driving 
force for glutamate uptake. Trophic factors like BDNF, GDNF, NGF, IGF and thrombospondin, produced 
and released by astrocytes regulate synapse formation, maintenance and remodelling. Glutamatergic 
activation induces lactate release from astrocytes via monocarboxylate transporters (MCT). Astrocytes 
also control water and ion exchange in the synaptic cleft through water (AQP4) and ion (Kir4.1) channels 
and ion exchangers (Na+/H+ exchanger, Na+/Ca+2 exchanger). Kir4.1 is the main channel involved in 
potassium buffering in astrocytes. K+ ions travel through the astrocyte syncytium via gap junctions or 
are siphoned in the blood circulation. Carbonic anhydrase (CA) in astrocytes converts CO2 into H
+ and 
HCO3-. Two HCO3- are transported into the extracellular space along with one Na+ via the Na+-HCO3- 
co-transporter (NBC), thereby increasing the extracellular ion buffering power. Excess H+ in neurons is 
extruded via the Na+/H+ exchanger (NHE).
Translational Neuroscience
146
(BDNF), glial cell derived neurotrophic factor 
(GDNF), nerve growth factor (NGF), insulin-like 
growth factor (IGF) and thrombospondin [9-
12]. Additional factors produced by astrocytes 
like cholesterol, apolipoprotein E, glutathione 
and hydrogen sulphide have been shown to 
modulate neuronal function and viability in in 
vivo and in vitro models (reviewed by [13]). In 
the adult CNS protoplasmic astrocytes extend 
many fine processes that can contact synapses. 
It has been estimated that in the hippocampus 
and cerebral cortex a single astrocyte contacts 
100.000 or more synapses establishing a 
highly regulated, bidirectional communication 
[14,15]. Astrocytes possess functional receptors 
for the uptake of neurotransmitters and 
themselves respond to neurotransmitter 
stimulation via release of transmitter molecules 
called “gliotransmitters”. The uptake of the 
neurotransmitter glutamate is one of the most 
important functions of mature protoplasmic 
astrocytes. L-glutamate is the major excitatory 
amino acid in the CNS and its clearance 
by astrocytes is mainly due to high affinity 
glutamate transporters: excitatory amino acid 
transporter 1 (EAAT1) and particularly EAAT2 
in human brain, named glutamate aspartate 
transporter (GLAST) and glial glutamate 
transporter 1 (GLT1) in murine brain,  respectively 
[16,17]. Astrocytes also express ionotropic 
and metabotropic glutamate receptors whose 
activation mainly leads to Ca2+ influx [18]. 
Although both neurons and astrocytes express 
glutamate transporters, glutamate entry into 
astrocytes is the predominant route for removal 
of this excitatory neurotransmitter from the 
synaptic cleft and is responsible for 90% of total 
glutamate uptake as observed in in vitro and 
in vivo experiments [16,18]. Glutamate uptake 
by astrocytes maintains low extracellular 
glutamate concentrations, thus providing 
protection to neurons from excitotoxicity [16]. 
Dysfunction of EAAT2 and accumulation of 
excessive extracellular glutamate have been 
implicated in the development of several 
neurodegenerative diseases (see Table 1). 
Glutamate transporters are membrane-bound 
pumps closely resembling ion channels which, 
by using the Na+ gradient generated by the Na+, 
K+-ATPase pump, uptake glutamate along with 
Na+ ions and import them into the astrocyte 
cytosol. After uptake by astrocytes glutamate 
is amidated by the astrocyte specific enzyme 
glutamine synthetase to form the neuronal 
nonreactive amino acid glutamine. The latter is 
released back in the extracellular space to fuel 
neurons where it is reconverted into glutamate 
in a process called the glutamate-glutamine 
cycle [19,20]. Mature astrocytes in situ are 
also involved in the uptake of other active 
neurotransmitters like gamma-aminobutityric 
acid (GABA), norepinephrine, dopamine, 
serotonin, acetylcholine and glycine [21] 
through specific transporters that are expressed 
at high levels in astrocytic endfeet contacting 
the synapses [15,22,23].
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Table 1.  Astrocyte contribution to CNS pathology*.
* Infectious and tumoral diseases are not included in this table. **α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptors (AMPARs)
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Increasing experimental evidence indicates 
that gliotransmitters released from astrocytes 
actively participate in modulating synaptic 
activity. Astrocytes react to synaptically 
released neurotransmitters with intracellular 
calcium elevations, which in turn induce the 
regulated secretion of gliotransmitters, such 
as glutamate, adenosine triphosphate (ATP), 
GABA and D-serine [24], mainly through 
Ca2+-dependent vesicular release ([25] 
and references therein) but also via other 
mechanisms (reviewed by [26,27]). Release 
of gliotransmitters is also driven by a volume 
regulatory response stimulated by osmotic 
imbalance conditions following the release of 
osmotically active solutes from the neuronal 
cytoplasm into the extracellular space [27]. 
These findings have led to build-up a new 
model of neuron-glia inter-communication, 
the so called “tripartite synapse”, comprising 
the pre- and post-synaptic neurons and the 
astrocyte, where the latter integrates neuronal 
inputs and modulates synaptic activity [22]. 
Other soluble factors produced by astrocytes 
in vitro and in vivo, such as neurosteroids [28], 
growth factors and cytokines [29], can also 
influence synaptic activity.
Astrocytes also support brain activity by 
supplying neurons with energy substrates. 
They contribute to take up glucose, the primary 
source of energy for the brain, from the blood 
circulation and to deliver it to neurons. Apart 
from neurons which mainly rely on oxidative 
metabolism, astrocytes rely more on glycolytic 
metabolism to generate ATP and lactate from 
glucose [30,31]. Glucose enters astrocytes via 
specific glucose transporters (GLUT) and its 
degradation to lactate represents the main 
energy source for neurons, particularly during 
intense neuronal activity. In the “astrocyte-
neuron lactate shuttle model” (ANSL) 
proposed by Magistretti and collaborators 
[32] astrocytes respond to glutamatergic 
activation by increasing the rate of glucose 
utilization and the production of lactate which 
is released in the extracellular space through 
monocarboxylate transporters to be taken up 
by neurons (reviewed by [33] and references 
therein). Neurons can use both lactate and 
glucose as energetic substrates, and the 
issue of lactate versus glucose as energetic 
supply for neurons has been debated [34]. 
Moreover, the CNS astrocytes represent the 
main storage site for glycogen [35]. Up to 40% 
of glucose entering astrocytes is metabolised 
into glycogen molecules which can be rapidly 
mobilized without requirement of ATP to 
generate energy substrates, particularly lactate 
([33] and references therein). In areas of intense 
synaptic density the accumulation of glycogen 
in astrocytes is increased and its utilization 
can sustain neuronal activity [35] but also 
buffer blood hypoglycaemia which disturbs 
cerebral metabolism and neuronal function 
[36,37]. The coupling between astrocyte 
glycogen accumulation and its mobilization 
during neuronal activity is sustained by 
the observation that neurotransmitters like 
glutamate can regulate glycogen release at 
synaptic sites ([33] and reference therein). The 
activity-dependent mechanisms of glucose 
utilization involve Na+-coupled glutamate 
uptake in astrocytes and the activation of the 
Na+, K+-ATPase which triggers glucose uptake 
from the blood and its processing [38].
Another important task of astrocytes is to 
optimize synapse functionality by maintaining 
the interstitial space homeostasis through a 
tight control of water and ion fluxes [39]. To 
this end, astrocytes are well equipped with ion 
channels and transporters for the uptake of K+ 
ions and for proton exchange, like the Na+/H+ 
exchanger, bicarbonate transporters, and the 
vacuolar type ATPase [40]. It is remarkable that 
most of the ATP produced within astrocytes is 
for cell pumping requirements to maintain ionic 
homeostasis [31]. Particularly important is the 
astrocyte-mediated control of K+ homeostasis 
since repetitive firing of action potentials in 
neurons induces a rise in extracellular K+ ions 
that can compromise neuronal function, if not 
quickly buffered in the space surrounding the 
synapses [41]. Studies in cultured cells have 
demonstrated that astrocytes have a much 
higher capacity for K+ uptake compared to 
neurons [42]. It was initially proposed that 
astrocytes, due to their high permeability to K+ 
ions, could favour passive uptake of K+ ions that 
would diffuse to distant sites through the glial 
syncytium, a process named K+ spatial buffering 
[41,43]. More recently using knock-out (KO) 
mouse models it has been demonstrated that 
K+ spatial buffering, rather than being a passive 
process, is mediated by the activity of specific 
channels, particularly the inward-rectifying 
Kir4.1 channels [44] which are clustered in 
specific functional domains in the perisynaptic 
and perivascular astrocyte endfeet. Due to the 
weakly rectifying nature of Kir4.1 the same 
channel can drive both inward and outward K+ 
movements in astrocytes [45]. Other molecules 
like the Na+, K+-ATPase pump, co-transporters 
of the Slc12a family and chloride channels 
contribute to K+ buffering by astrocytes as 
observed in vitro and in vivo models [42,46-48].
Astrocytes and blood vessels: the 
vascular domain (Figure 2)
Both protoplasmic and fibrous astrocytes 
contact and establish bidirectional 
communication with BBB components [49]. The 
BBB is a diffusion barrier that hampers entry of 
most of the molecules and cells present in the 
blood into the brain parenchyma, maintaining 
the specific microenvironment required for 
proper brain functioning. The BBB consists 
of specialized endothelial cells lining brain 
capillaries which form tight junctions between 
them and are surrounded by pericytes, basal 
lamina and astrocyte endfeet in a concentric 
manner on their abluminal side [50]. 
Pericapillary astrocyte endfeet are involved 
in the control of the ingress of nutrients, like 
glucose and amino acids, from the blood 
circulation by means of specific transporters, 
and the egress of waste metabolites [51]. 
Pericapillary astrocyte endfeet are also 
enriched in the water channel aquaporin 4 
(AQP4), which is anchored to the membrane 
by the dystrophin-associated protein complex 
and functionally cooperates with Kir4.1 to 
regulate water and K+ exchange at these sites 
[52-54]. Other ion channels involved in the 
control of cell volume [55-57], like the chloride 
channel ClC2, the calcium channel transient 
receptor potential vanilloid-4 cation channel 
(TRPV4) and the putative ion channel MLC1 are 
enriched in astrocyte endfeet contacting blood 
vessels and the pial membrane [55,58,59]. 
Numerous observations indicate that both 
astrocyte interactions and astrocyte-derived 
factors among which peptides, growth factors, 
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cytokines, chemokines, lipid substances 
and neurotransmitters, are essential for the 
development and/or maintenance of the BBB 
properties of brain endothelial cells [60,61]. In 
cell culture systems also endothelial cells can 
influence astrocyte growth and differentiation 
[62] in a bidirectional cross-talk. Because of 
their polarized anatomical structure and of 
the vicinity of their endfeet to the contractile 
elements of blood vessels, such as smooth 
muscle cells in arterioles and pericytes in 
capillaries, astrocytes have been long proposed 
to contribute to the regulation of the blood flow 
during neuronal activity. Indeed, astrocytes are 
able to influence local blood flow in the CNS 
through release of vasoactive substances like 
prostaglandins (PG), arachidonic acid (AA) and 
nitric oxide (NO) which regulate vessel diameter 
and blood flow in a coordinated manner [63,64]. 
Notably, astrocytes regulate vasodilatation and 
blood flow in response to electrical activity 
so that neuronal metabolism is supported by 
adequate perfusion of brain tissue [65,66]. This 
process, known as neurovascular coupling or 
functional hyperemia, is essential for cerebral 
homeostasis and neuronal survival. Ca2+ 
signals that travel along astrocytic processes 
activate the release of vasoactive substances 
causing relaxation, and in some circumstances 
contraction, of the smooth muscle cells of 




Astrocytes contact neighbouring astrocytes 
via gap junctions (GJ), which are a specialized 
type of junctions formed by clusters of closely 
packed hemichannels named connexins 
aligning between adjacent cells [68]. GJ 
mediate cell-cell adhesion and allow the 
communication and functional coordination of 
contacting cells through the direct cytoplasmic 
passage and exchange of ions, mainly Ca2+ 
but also K+ and Na+, and small molecules 
such as water, glucose, metabolites, second 
messengers and neurotransmitters [69]. 
Unopposed hemichannels can also open 
on the cell surface and are involved in the 
release of different intracellular molecules 
Figure 2.  Astrocytes and the blood brain barrier. The blood brain barrier (BBB) structure relies on the properties of 
endothelial cells of brain capillaries which are sealed by tight junctions and surrounded by basal lamina, 
pericytes and astrocyte endfeet. The water channel aquaporin-4 (AQP4) and the potassium channel 
Kir4.1 involved in water and potassium exchange are enriched in the membranes of astrocytic endfeet 
where they are stabilized by the association with the dystrophin-dystroglycan associated complex 
(DGC). At this site astrocyte endfeet are highly enriched in ion channels among which the chloride 
channel ClC2, the calcium channel TRPV4 and the putative ion channel MLC1. Uptake of glucose from 
the blood circulation by astrocytes occurs via the glucose transporter-1 (GLUT1).
Figure 3.  Astrocyte-astrocyte syncytium. Astrocytes are interconnected via gap junctions formed by clusters of 
packed connexin (Cx) hemichannels that contribute to form an astrocyte syncytium for the exchange 
of small molecules (water, glucose, metabolites, second messengers and neurotransmitters) and ions 
(Ca+2, K+ and Na+) over long distances. Na+ and Ca+2 diffuse through gap junctions in the astrocyte 
syncytium generating signalling and metabolic waves.
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into the extracellular space. In the CNS, glial 
cells express the highest level of connexins 
(connexins 30 and 43 representing the main 
astrocyte specific connexins), GJ channels and 
hemichannels ([69] and references therein). By 
means of GJ astrocytes form a network that is 
visualised experimentally by the injection of a 
dye in one cell and its subsequent spreading 
to adjacent cells. Astrocyte coupling generates 
a multicellular structural and functional 
network, considered as a syncytium, that is 
not only essential for physiological functions 
but may also play a role in CNS disorders [70]. 
Through this network astrocytes are thought 
to rapidly dissipate K+ and glutamate from 
highly active synapses to other brain areas 
or blood circulation, avoiding their harmful 
accumulation [71]. Passage of Ca2+ ions between 
adjacent astrocytes provides these cells with a 
specific form of excitability and represents the 
major way by which astrocytes encode and 
transmit information. During the propagation 
of Ca2+ waves several calcium-dependent 
pathways and biochemical cascades are 
activated which have functional consequences 
for astrocyte themselves and for neighbouring 
cells (for a detailed review see [72]). Connexins 
also allow direct contacts between astrocytes 
and oligodendrocytes (see below).
It has been shown that, in addition to Ca2+ 
waves, electrical or mechanical stimulation of 
cultured astrocytes induces metabolic waves 
that are mediated by Ca2+-dependent release of 
glutamate which in turn triggers a Na+ wave in 
the astrocyte network due to the activity of the 
Na+-dependent glutamate transporters [72,73]. 
The propagation of this signal is spatially and 
temporally connected with the activation of 
glucose uptake, which is also dependent on 
astrocyte glutamate transporters, thus allowing 
a concerted neurometabolic coupling between 
glucose utilization and neuronal activity [74]. 
The important role of Ca2+ and Na+ ions in 
regulating astrocyte function is demonstrated 
by the tight control of the intracellular 
concentration of these two ions exerted by 
several transporters and ionic channels or ion 
exchangers present in the astrocyte plasma 
membrane [75]. In light of these findings 
neuron-glia relationships should be considered 
not only at the single cell level, but as a 
more complex array of interactions between 
neuronal and glial networks.
Astrocyte relationships with 
oligodendrocytes and myelin 
(Figure 4)
Astrocyte production of growth factors 
which promote neuronal survival in normal 
([76], see above) and injured brain [77] is also 
essential for survival of oligodendrocytes, 
the myelin forming cells. The importance of 
astrocytes as regulators of oligodendrocyte 
proliferation and differentiation in vitro was 
recognized more than 20 years ago when 
astrocytes were identified as a major source 
of proliferation and differentiation factors, 
in particular platelet-derived growth factors 
(PDGFα) and fibroblast growth factor 2 (FGF2), 
for oligodendrocyte progenitor cells [78-80]. 
Subsequently, astrocyte-conditioned media 
and several astrocyte-derived soluble factors, 
like neurotrophin-3 (NT-3), IGF-1 and ciliary 
neurotrophic factor (CNTF), were found to 
support oligodendrocyte progenitor cell 
survival [81-83]. Although astrocytes have 
long been considered the main players in 
the inhibition of CNS repair via formation of 
the glial scar (see below), it is now accepted 
that astrocytes regulate myelin formation 
and that understanding this process could 
help develop strategies for CNS repair and 
remyelination [84]. Astrocyte influence on 
myelination is supported by the observation 
that oligodendrocytes remyelinate 
preferentially in areas containing astrocytes 
and that endogenous remyelination can be 
favoured by transplanting astrocytes into 
demyelinated lesions [85,86]. In vitro studies 
using a myelinating culture system made 
of embryonic spinal cord cells plated on 
monolayers of astrocytes provided additional 
evidence that astrocytes, particularly when 
activated, efficiently support myelination by 
secreting pro-myelinating factors [87,88]. 
Moreover, depending on their activation 
status astrocytes can promote myelination 
by releasing cytokines and growth factors 
like BDNF, CTNF, GDNF, IGF, NGF, C-X-C motif 
chemokine 12 (CXCL12), PDGF, FGF and factors 
implicated in extracellular matrix remodelling 
which may affect oligodendrocyte progenitor 
Figure 4.  Astrocyte relationship with oligodendrocytes and myelin. Astrocytes produce several factors that 
contribute to oligodendrocyte progenitor cell (OPC) proliferation and differentiation, such as PDGFα 
and FGF2, and survival like NT-3, IGF-1, CNTF. Astrocytes also respond to ATP released by neurons 
by producing LIF which promotes the myelinating activity of oligodendrocytes. Astrocytes may also 
contribute to myelin maintenance via gap junction communication.
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proliferation/differentiation or even the 
process of myelin ensheatment [40,84].
Astrocytes can modulate myelin formation 
by indirectly connecting neuronal activity with 
myelinogenesis. Co-culture studies indicated 
that electrical activity induces neurons to release 
ATP, which serves as an important stimulus 
for myelin formation by inducing astrocytes 
to secrete leukemia inhibitory factor (LIF), a 
regulatory protein that promotes the myelinating 
activity of oligodendrocytes [89]. Astrocytes 
may also contribute to myelin maintenance 
through gap junction communication as 
demonstrated by presence of extensive white 
matter vacuolation and myelin degeneration in 
mice double-deficient for connexins that form 
heterotypic interactions between astrocytes and 
oligodendrocytes [90-92]. 
Astrocytes in brain pathology 
(Table 1)
Considering the essential role played by 
astrocytes in the maintenance of CNS 
homeostasis and function, it is conceivable 
that any alteration of astrocyte-mediated 
physiological processes may directly cause or 
contribute to CNS pathology. The emerging 
view is that astrocyte homeostatic failure is 
implicated in neurological symptoms and in 
processes leading to neurodegeneration that 
once were considered to be due only to neuron 
dysfunction [93]. Indeed, astrocytes have 
been demonstrated to play an important role 
in the pathogenesis of several CNS diseases 
[94-111]. In addition, the molecular apparatus 
that controls brain homeostasis can turn 
to be deleterious and toxic in conditions of 
severe insults or when abnormally stimulated 
[93]. Expression of aquaporins in perivascular 
astrocyte membranes, which is essential to 
regulate water exchange in the brain and also 
responsible for the generation of cerebral 
edema during stroke [112], is a clear example 
of astrocyte gain-of-function-mediated 
pathological effect. In general, astrocytes 
respond to CNS injury with a spectrum of 
molecular, cellular and functional changes that 
lead to progressive hypertrophy, proliferation, 
process extension and interdigitation and 
reversible alteration of gene expression. 
This gradual process of astrocyte activation 
or astrogliosis can lead to long lasting glial 
scar formation depending on the nature of 
the insult [40,93,113]. It is widely recognised 
that the spatial, temporal and insult specific 
regulation of astrocyte reactivity contributes to 
limit tissue damage [114] and that alterations 
in astrocyte activation can lead to neural 
dysfunction as observed in trauma, stroke 
and multiple sclerosis [40]. However reactive 
astrogliosis can exert detrimental effects 
at different levels, such as exacerbation of 
inflammation via cytokine production, release 
of toxic substances [glutamate, reactive oxygen 
species (ROS)], alterations of the BBB structure 
and function through vascular endothelial 
growth factor (VEGF) production, or AQP4 
overactivity which can lead to cytotoxic edema 
in trauma and stroke [40,112,115,116]. Similarly, 
glial scar formation, which is beneficial to 
encapsulate infections and areas of tissue 
necrosis, can be deleterious for tissue repair 
[113]. The observation that glutamate release 
from astrocytes is controlled by molecules 
linked to inflammation, such as tumor necrosis 
factor (TNF) and PG [117], suggests that glia-to-
neuron signalling is affected by inflammatory 
responses. In view of this increasing basic 
knowledge, it is not surprising that the list of 
CNS diseases in which astrocyte dysfunction 
and hyper-reactivity play a pathological role is 
continuously expanding [93]. 
Astrocytes as direct targets of 
pathological processes (Table 2) 
In some neurological diseases a specific 
pathological process can primarily affect 
astrocytes causing their dysfunction. Among 
these, neuromyelitis optica is an inflammatory 
demyelinating disease that is associated with an 
autoantibody response directed against AQP4, 
the water channel expressed at high density 
in perivascular, subpial and subependymal 
astrocyte endfeet [118]. Anti-AQP4 
autoantibodies have a primary role in disease 
pathogenesis by disrupting the structural 
and functional integrity of astrocytes, leading 
to demyelination and axonal loss primarily 
in spinal cord and optic nerve, paralysis 
and blindness [119,120]. Even if conditional 
deletion of AQP4 in astrocytes alone does not 
lead to a neurological phenotype [121], these 
studies indicate that autoimmune events that 
target astrocytes can induce demyelination 
and neurodegeneration. Autoantibody-
independent AQP4 and Cx43 decrease is also 
observed in Balò’s disease, a rare inflammatory 
demyelinating disease characterized by brain 
lesions with concentric areas of demyelination 
alternated with preserved myelin layers [122]. 
Disruption of astrocyte-oligodendrocyte 
interactions due to astrocyte dysfunction and 
loss is suggested as a pathological mechanism 
of this disease [122,123]. 
In Wernicke’s disease a neurological disease 
resulting from dietary thiamine (vitamin B1) 
deficiency and clinically characterized by 
changes in consciousness, ocular dysfunction 
Disease Neuropathological features Astrocyte-associated defect References
Neuromyelitis Optica (NMO)
Inflammatory  autoimmune demyelinating disease associated 
with demyelination, astrocyte loss and neuronal degeneration
Autoantibody-mediated loss of 
AQP4+ and GFAP+ astrocytes
118
Balò’s disease
Inflammatory demyelinating disease characterized by concentric 
demyelinating lesions and astrocyte hypertrophy




Metabolic encephalopathy associated with brain damage, 
edema, loss of neurons, gliosis 
Loss of EAAT1 and EAAT2, decrease 
in AQP4 and glutamine synthetase 
124-126
Hepatic encephalopathy Cytotoxic brain edema
Ammonia and glutamine-induced 
astrocyte swelling, neurotransmitter 
receptor alterations
127-129
Table 2.  Neurological diseases associated with astrocyte dysfunction.
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and ataxia, decrease of the astrocytic glutamate 
transporters EAAT1 and EAAT2 and disturbance 
of glutamatergic neurotransmission are 
considered the main cause of the loss of neurons, 
gliosis [124] and structural damage (lesions 
in thalamus and cortex) observed in patients 
[106]. Abnormalities in GABA transporters, GFAP, 
glutamine synthetase, and AQP4 have also been 
reported, which may result in brain edema, 
oxidative stress, inflammation and white matter 
damage [124-126]. Hepatic encephalopathy, 
an alteration of the CNS primarily caused 
by hepatic insufficiency, liver failure and 
cirrhosis, results in a decrease in ammonia 
detoxification and higher ammonia levels in 
the systemic circulation. Excessive ammonia 
entry into the brain leads to astrocyte swelling. 
Swelling impairs astrocyte homeostatic ability 
and predisposes to neuronal dysfunction 
and cytotoxic brain edema, the major cause 
of mortality [127]. Hepatic encephalopathy 
is considered as a primary astrocytopathy 
[128,129] since astrocytes are the only CNS cell 
type that can detoxify ammonia by glutamate 
to glutamine conversion.
Astrocyte dysfunction as primary 
cause of brain diseases: focus on 
cystic leukodystrophies (Table 3)
The first example of a disease with a primary 
astrocyte defect is Alexander’s disease (AxD), 
a leukodystrophy in which mutations in the 
gene encoding the astrocyte intermediate 
filament GFAP causes severe myelin 
alterations and neurodegeneration [130,131]. 
Leukodystrophies are a heterogeneous 
group of rare and untreatable genetic 
diseases characterised by defects in CNS 
myelin formation or maintenance. Most 
leukodystrophies manifest as early as in the first 
year of life or later in childhood or adolescence 
and represent an important cause of progressive 
mental and motor disability. Although 
considerable advances in the diagnosis 
have been made over the last decade due to 
improvement in magnetic resonance imaging 
(MRI) and gene sequencing technology, the 
definitive diagnosis of many leukodystrophies 
remains a challenge and requires combined 
clinical, genetic, biochemical and 
neuroradiological investigations [132]. Most of 
the clinically characterized leukodystrophies 
are still of unknown cause, while in some cases 
the gene mutation is known but the function 
of the mutated proteins or the pathogenetic 
mechanisms leading to myelin defects remain 
elusive [133]. Pathological mutations can 
target genes encoding myelin components or 
genes encoding proteins whose dysfunction 
indirectly leads to myelin damage. Different 
types of classification of these myelin 
disorders have been made based on either 
pathological defect, biochemical and genetic 
data or on the combination of histological 
and clinical criteria [134]. Depending on the 
type of defect observed, leukodystrophies 
have been classified into 2 main groups: i) 
hypomyelinating leukodystrophies, in which 
a lower amount of myelin is observed due to 
defects in myelin production or to myelin poor 
quality, are generally caused by mutations in 
genes encoding myelin structural proteins, 
such as myelin proteolipid protein (PLP) 
[135]; and ii) demyelinating leukodystrophies 
in which myelin degenerates because of 
loss of some enzymatic activity essential for 
myelin biogenesis and maintenance, like 
peroxisomal or lysosomal enzymatic activities, 
or because of astrocyte dysfunctions that lead 
to progressive cystic or spongy (vacuolating) 
degeneration of myelin [135,136]. This latter 
group encompasses AxD, megalencephalic 
leukoencephalopathy with subcortical cysts 
and vanishing white matter disease, three 
leukodystrophies characterized by defects in 
genes expressed in astrocytes or associated 
with specific astrocyte function (Table 3). In 
the next section the role of astrocytes in these 
leukodystrophies is discussed. The clinical and 
neuropathological characterization of these 
diseases has been described in detail elsewhere 
[137-139].
Alexander’s disease (AxD)
AxD (OMIM 203450) is a degenerative 
neurological disorder that is inherited in an 
autosomal dominant manner and is caused 
by heterozygous mutations in the astrocyte 
specific type III intermediate filament GFAP 
gene [132]. About 95% of patients show 
Table 3.  Leukodystrophies caused by a primary astrocyte defect.
Leukodystrophy Gene defect Astrocyte-mediated pathological mechanisms
Clinical and histopathological features
shared among cystic leukodystrophies 
Alexander’s disease (AxD)
Mutations in the 
glial fibrillary acidic 
protein (GFAP) gene  
(130)
Accumulation of Rosenthal 
fibers, abnormal GFAP 
polimerization, defects in 
proteasomal degradation and 
authophagy processes, decrease 
in glutamate trasporters
Macrocephaly, ataxia, spasticity, epilepsy,
aggravation of clinical conditions after minor head trauma 
and infections; limited genotype-phenotype correlation. 




Mutations in the 
MLC1 or HEPACAM 
gene
(168,178)
Altered regulation of ion and 
fluid homeostasis and cell 
volume
Macrocephaly, ataxia, spasticity, mild cognitive decline, 
severe motor dysfunctions, epilepsy, subcortical cysts, 
aggravation of clinical conditions after minor head trauma. 
No genotype-phenotype correlation. 
Swollen white matter, astrocyte vacuolation
Vanishing white matter 
syndrome (VWM) or childhood 
ataxia with central nervous 
system hypomyelination (CACH) 
Mutations in the 
Eukariotic Translation 
Initiation Factor 2 
(EIF-2B) gene (187)
Astrocyte maturation defect, 
abnormal response to stress 
conditions 
Ataxia, spasticity, loss of vision, severe motor dysfunctions, 
mild cognitive decline, epilepsy, aggravation of clinical 





mutations, including de novo mutations, in the 
GFAP gene. Mutations can affect different parts 
of the GFAP protein, at either the NH2 or COOH 
terminal, with hot spot mutation areas [140]. 
Evidence of genotype-phenotype correlation in 
AxD is limited [141]. Three forms of the disease 
exist: infantile, juvenile and adult-onset. The 
infantile onset form is very aggressive and is 
characterized by seizures, bulbar dysfunction, 
psychomotor regression symptoms and low 
life expectancy [142]. When compared to a 
healthy control (Figure 5A-D) MRI analysis 
of AxD affected brain reveals macrocephaly 
and widespread abnormalities in the anterior 
white matter (Figure 6 A-D). The juvenile and 
adult forms of AxD are not associated with 
macrocephaly, have longer life expectancy and 
milder symptoms, white matter damage being 
less severe and sometimes absent. Aggravation 
of clinical symptoms can occur after trauma 
or inflammatory events [140,142-144].
Histopathological studies performed on bioptic 
and autoptic brain samples indicate that 
pathological changes in the CNS of aggressive 
infantile forms include loss of oligodendrocytes, 
cystic degeneration and loss of myelin in the 
white matter and variable loss of neurons, most 
commonly in the hippocampus, striatum, and 
neocortex [145,146].
The pathological hallmark of AxD is 
the presence of Rosenthal fibers, that are 
ubiquitinated protein aggregates composed 
of GFAP, vimentin, small heat shock proteins 
(including αB-crystallin and Hsp27) and 
plectin, in the cytoplasm of astrocytes 
[147,148]. Since GFAP is not expressed 
in neurons or oligodendrocytes, myelin 
degeneration and oligodendrocyte loss in the 
AxD brain [149] are secondary to alterations in 
astrocyte functions [137]. A direct relationship 
between expression of disease-associated 
GFAP mutants, Rosenthal fiber accumulation 
in astrocytes and neurodegeneration was 
demonstrated first in mice carrying additional 
copies of the wild-type human GFAP gene and 
expressing elevated levels of GFAP protein, 
which replicated some features of human AxD, 
and in knock-in mice carrying the pathological 
gene mutations found in patients [149,150]. 
While these studies suggest that high levels 
of wild-type GFAP can reproduce the astrocyte 
phenotype of AxD, studies performed in 
cultured astrocytes showed that mutant GFAP 
protein accumulates more rapidly and at higher 
levels than the wild-type protein [151,152]. 
Thus, the precise mechanism through which 
GFAP mutations lead to accumulation of 
Rosenthal fibers and the pathogenicity of the 
proteinaceous aggregates themselves are not 
completely understood. The dominant nature 
of pathological GFAP mutations, along with the 
accumulation of protein aggregates in brain 
astrocytes, have led to a hypothesis of a toxic 
gain-of-function pathological mechanism with 
impairment of normal astrocyte supportive 
functions [153]. Other studies have suggested 
that astrocyte-mediated pathological effects 
in AxD are due to both oxidative stress and 
reduction in glial glutamate transporter 
function [154-156]. It was been shown that 
GLT-1 transcript and protein are markedly 
downregulated in astrocytes overexpressing 
mutant GFAP and that hippocampal neurons 
are more vulnerable to glutamate-induced 
excitotoxicity when co-cultured with 
astrocytes overexpressing mutant GFAP [157]. 
These observations connect GFAP mutations 
to GLT-1 dysfunction and impairment of 
neuron-astrocyte interactions, suggesting a 
Figure 5.  Normal MRI of a 4 year old boy. (A) Normal myelination in a T2 weighted image; (B) the same aspect 
in a FLAIR weighted image with normal relative hypointensity of the white matter; (C) the normal 
hypointense T2 weighted signal also involves the white matter of the cerebellum; (D) relative 





possible pathogenic mechanism underlying 
neuronal loss in AxD. However, failure of 
other astrocyte homeostatic functions, like 
extracellular K+ buffering via Kir4.1 and Na+, 
K+-ATPase activity, has been recently proposed 
to contribute to myelin degeneration in 
AxD [149]. In vitro studies have provided 
additional clues to AxD pathogenesis 
supporting a critical role for abnormalities in 
protein degradation pathways in astrocytes, 
including impairment in proteasome activity 
and autophagy [151-153, 158-160]. Multiple 
vacuoles, mostly autophagic vacuoles, 
have been found in astrocytes in AxD brain 
specimens and in the brain of knock-in mice 
[158] suggesting that GFAP mutants can 
induce astrocyte degeneration by activating 
abnormal autophagic processes. 
Megalencephalic leukoencepha-
lopathy with subcortical cysts (MLC)
MLC (OMIM 604004) is a rare congenital 
and autosomal recessive leukodystrophy 
characterized by early-onset macrocephaly, 
fronto-temporal subcortical cysts and swollen 
appearance of the white matter, as observed 
by magnetic resonance imaging (MRI) analysis 
[161] (Figure 7A-D). Ataxia, seizures, motor 
function degeneration and epilepsy occur 
during the course of the disease and are 
associated with late-onset mild cognitive 
impairment [161-164]. Temporary aggravation 
of clinical symptoms after minor head trauma 
has been reported [165-167]. Histological 
analysis of brain biopsies from MLC  subjects 
revealed spongy degeneration of myelin, 
with vacuoles localised in the outer layers 
of the myelin sheats, variable alterations of 
the BBB structure and astrocyte activation 
[168,169]. Enlarged vacuoles localized in 
the endfeet of blood vessel-contacting 
astrocytes have been described [170,171]. 
Almost 75% of MLC patients carry mutations 
(missense, splice site, insertions and 
deletions) in the MLC1 gene [168,172-174].
However, no correlation between genotype 
and phenotype has been reported so far. 
Different clinical manifestations have been 
observed in MLC patients carrying the same 
mutations suggesting that epigenetic factors 
can influence the disease course. The human 
MLC1 gene encodes a 377-amino acid protein 
named MLC1. This is an oligomeric protein 
with eight predicted transmembrane domains 
with low homology with ion channels and 
transporters [58,168,174,175] whose exact 
function is still unknown. Studies in human 
and murine brain indicate that MLC1 is 
mainly expressed in perivascular and subpial 
astrocyte endfeet contacting blood vessels 
and the pial membrane and in intracellular 
structures in parenchymal astrocytes 
(Figure 8A-C). Moreover, cerebellar Bergmann 
glia and ependymal cells lining the ventricles 
are other brain cells expressing MLC1 
[174-177]. The selective localization of MLC1 
in distal astrocytic processes ensheating 
blood vessels renders this protein a candidate 
molecular marker to specifically identify these 
astrocytic subdomains. Recently, mutations in 
the hepatic and glial cell adhesion molecule 
gene (Hepacam/Glialcam) encoding an 
adhesion-like molecule of unknown function 
have been found in the majority of MLC 
patients without mutations in MLC1, indicating 
genetic heterogeneity [178,179].
Figure 6.  MRI of a 22 month old boy with macrocephaly  harboring a  heterozygous  mutation in GFAP. (A) Notice 
the hyperintesity of the abnormal signal in T2 weighted image predominant in the anterior white matter 
sparing the U fibres only in the posterior white matter regions; (B) the same areas  appear markedly 
hypointense in the correspondent anterior white matter regions in the T1 weighted images; (C) the 
abnormal hyperintense T2 weighted signal also involves the white matter of the cerebellum;  (D) the 






In cultured human and rat astrocytes MLC1 
is localized along the plasma membrane, at 
astrocyte-astrocyte contacts and in many 
intracellular vesicles [170,180,181]. As for GFAP 
in AxD, MLC1 is an astrocyte specific protein 
not found in oligodendrocytes [174-176], 
indicating that also in MLC myelin degeneration 
is secondary to astrocyte dysfunction. To date 
the molecular mechanisms causing MLC-
associated brain damage are not completely 
understood. Swollen white matter, fluid cysts 
and myelin vacuolation observed in the MLC 
brain and preferential localization of MLC1 at 
the brain barriers has led to suggest that MLC1 
is involved in astrocyte-mediated regulation 
of brain homeostasis through transport of 
water and/or ions between astrocytes and 
the blood or cerebrospinal fluid. Consistent 
with this hypothesis we have recently shown 
that in cultured astrocytes MLC1 interacts 
with the b subunit of the Na+, K+-ATPase 
complex and is part of a macromolecular 
protein complex that includes Kir4.1, AQP4, 
syntrophin, dystrobrevin, caveolin-1 and the 
cation channel TRPV4. This complex is involved 
in the cellular response to hyposmotic stress in 
primary rat astrocytes and human astrocytoma 
cells overexpressing MLC1 [182,183]. We have 
shown that MLC1 functionally cooperates 
with TRPV4 to activate intracellular Ca2+ influx 
in astrocytes in hyposmotic conditions and 
that pathological MLC1 mutations affect 
this pathway [183]. TRPV4-mediated calcium 
influx is the trigger leading to activation of 
the regulatory volume decrease (RVD), which 
compensates hyposmotic stress-induced cell 
swelling, including astrocyte swelling [184,185]. 
Hyposmotic shock is known to cause an abrupt, 
osmotic driven cell swelling due to ion and 
water movement across the plasmalemma, 
which is followed by RVD activation. Together 
with the observation that ATP induces 
abnormal Ca2+ currents in patient-derived 
macrophages (Petrini S. et al., manuscript under 
revision) the data reported above, highlight 
the possibility that MLC1 mutations alter 
intracellular Ca2+ homeostasis which then leads 
to defects in cell volume regulation, particularly 
in stress conditions. Defects in a RVD-induced 
chloride current have been reported also in 
rat astrocytes upon siRNA-mediated MLC1 
downregulation and in MLC patient-derived 
lymphoblastoid cell lines after hyposmotic 
stimulation [56]. Altogether, these findings 
corroborate the idea that mutated MLC1 causes 
an altered reaction of astrocytes to osmotic 
changes, which accounts for brain damage in 
MLC. This model implies that MLC1 exerts its 
functions mainly in response to physiological 
changes in the extracellular ionic composition 
(i.e. during development or intense neuronal 
activity) or to pathological insults (i.e. trauma 
or inflammatory reaction). In this respect, we 
have observed upregulation of MLC1 protein 
expression in astrocytes in the brain of patients 
with the inflammatory demyelinating disease 
multiple sclerosis, [182] and other neurological 
diseases with a major microglia activation 
(Alzheimer’s disease, prion disease) (Sbriccoli, 
Ambrosini - unpublished data). The recent 
finding that the Hepacam/Glialcam protein is 
essential to transport MLC1 and the chloride 
channel ClC2, another channel involved in the 
regulation of cell volume in response to osmotic 
stress [57,179] in cultured rat astrocytes, 
supports the idea that alteration of this process 
is responsible for MLC pathogenesis. 
Figure 7.  MRI of a 8 month old boy with macrocephaly harboring a homozygous mutation in MLC1. (A) Notice 
the diffuse swelling aspect of the abnormal hyperintense signal in T2  weighted image also involving 
the internal capsule;  (B) the same areas appear markedly hypointense in the FLAIR weighetd images 
indicating  abnormal vacuolation of the white matter; (C) the abnormal hyperintense T2 weighted 
signal also involves the white matter of the cerebellum; (D) the diffuse swelling aspect with increased 





Vanishing white matter (VWM)
Leukoencephalopathy with vanishing white 
matter (VWM) (OMIM 603896), also called 
childhood ataxia with diffuse central nervous 
system hypomyelination (CACH), is an 
autosomal recessive disorder characterized 
by cerebellar ataxia, spasticity and cognitive 
decline [186]. Although initially described in 
children later studies demonstrated that VWM 
may affect people of all ages from neonates to 
adults. The disease shows a high variability in 
onset and symptom severity, which depend 
on patient specific gene mutations, genetic 
background and exposure to environmental 
stressors. Rapid neurologic deterioration 
following febrile infection, minor head trauma 
or acute fright is a hallmark of VWM disease. 
Epilepsy, hypotonia, vomiting and irritability 
are often associated with disease worsening. 
MRI and magnetic resonance spectroscopy are 
pathognomonic and in the typical childhood 
forms show a diffuse and symmetrical 
involvement of the cerebral white matter, which 
undergoes cystic degeneration (Figure  9A-D),
becomes progressively rarefied (vanishes) and 
is eventually replaced by cerebrospinal fluid 
[186]. Mutations in each of the genes encoding 
the five subunits of the eukaryotic translation 
initiation factor 2B (eIF2B) can cause VWM 
[187]. EIF2B is a ubiquitous factor that initiates 
the translation of RNA into protein and is 
involved in the regulation of this process, 
especially in stress conditions. More than 
120 mutations, mainly missense mutations, 
have been described in patients, without 
hotspot regions. Mutations in eIF2B result in 
abnormalities of its function [188] that lead 
to alteration of protein synthesis in control 
conditions and in response to stress when 
the cellular requirement of protein synthesis 
is increased. These effects may explain the 
sensitivity to stress factors observed in patients. 
However, the exact molecular mechanisms 
underlying white matter alterations in VWM 
are still under investigation. Although eIF2B is 
expressed in all cells, the pathophysiological 
effects of eIF2B mutations preferentially target 
white matter tracts resulting in extensive 
axonal loss [188-190]. Analysis of brain biopsies 
and autopsies revealed paucity of myelin 
despite an increased density of immature 
oligodendroglial cells in less affected regions, a 
variable portion of which display an abnormal 
“foamy” cytoplasm [191,192]. Poor astrogliosis 
and dysmorphic astrocytes [193] suggest 
the possible involvement of astrocytes in the 
pathogenesis of VWM disease. Consistent with 
this, it has been shown that the differentiation 
of GFAP+ astrocytes from neural progenitor 
cells was impaired in cultures established 
from the brain of patients with VWM disease 
and that the few astrocytes present in these 
cultures had an abnormal morphology and 
composition of the intermediate filament 
network [190]. In the same study the role of 
eIF2B in astrocyte development was confirmed 
using RNA interference technology [190]. A 
detailed histopathological study revealed that 
in VWM brain tissue astrocytes show increased 
proliferation capacity, defective maturation 
and altered composition of the GFAP network 
with increased levels of the delta GFAP isoform 
and of the protein chaperon aB crystallin 
[194]. These results suggest that defects 
in astrocyte function may contribute to or 
directly cause white matter damage in VWM 
disease. Abnormal myelination and an early 
defect in glial cell proliferation and maturation 
have been observed in mice carrying an 
homozygous mutations in the eIF2B gene 
[195]. However, the presence of GFAP+ cells 
in unaffected brain areas suggests that VWM 
pathogenesis can be the result of a complex 
interplay among different factors [194]. Studies 
performed in different cell culture systems, 
including those derived from patients, indicate 
that the decrease in eIF2B activity is more 
tightly related to alterations in the cellular 
stress response than to global protein synthesis 
inhibition. This could be due to the regulatory 
activity of eIF2B on endoplasmic reticulum 
stress response whose malfunctioning caused 
by gene mutations associated with VWM 
disease would lead to the generation of cells 
that are hyper-reactive to stress [196,197]. In 
this pathological scenario, it remains to be 
explained why, despite eIF2B is ubiquitously 
expressed, astrocytes and oligodendrocytes 
are the main targets of eIF2B mutation-
induced abnormalities. Recently, a microarrays 
analysis comparing fibroblasts from VWM 
patients, healthy controls and patients with 
other leukodystrophies revealed differences in 
the expression of specific genes involved in the 
Figure 8.  Co-immunostaining of normal human brain with anti-MLC1 (red) and anti-GFAP (green) antibodies. 
MLC1 is expressed in astrocyte end-feet contacting pial membrane (A, arrows) and blood vessels 
(arrowheads in A and in B) as indicated by the yellow signal in merged images. Scattered astrocytes in 
the parenchyma show MLC1 staining in vesicular structures in the cell body (C, asterisks). Bars  A=50 µm; 
B,C=20 µm. (Modified from Ambrosini et al., Mol. Cell. Neurosc., [177]).
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regulation of mRNA splicing and mitochondrial 
metabolism. In the same study splicing 
dysregulation of genes important for glial cell 
maturation, like PLP in oligodendrocytes and 
GFAP in astrocytes, were observed in eIF2B 
mutated fetal brains compared with control 
brains [136]. Another recent study showed in 
the brain of VWM patients accumulation of 
the high molecular weight extracellular matrix 
component hyaluronan [198], which inhibits 
oligodendrocyte and astrocyte progenitor cell 
differentiation [198-200], further supporting 
the pathogenetic importance of abnormalities 
in glial cell maturation processes in this disease.
Lesson from cystic 
leukodystrophies
The study of cystic leukodystrophies has 
revealed that failure of astrocyte functions 
due to specific gene mutations can lead to 
myelin degeneration. Although the molecular 
mechanisms underlying these diseases are not 
completely understood, it is now established 
that defects in astrocyte maturation, astrocyte 
functional impairment due to accumulation 
of toxic substrates, and/or failure of specific 
astrocyte-mediated homeostatic pathways 
can affect myelin formation and maintenance 
leading to cystic or spongiform myelin 
degeneration. Dysfunctional astrocytes 
could affect myelination also by acting on 
oligodendrocyte cell development. Whatever 
the mechanism leading to the astrocyte 
defect, an important concept that emerges 
from the study of leukodystrophies is that 
loss of astrocyte functionality can make the 
brain more vulnerable to changes in tissue 
homeostasis that are caused by different 
types of pathological insults and stress 
conditions, thus aggravating tissue damage. 
Indeed aggravation of clinical symptoms is 
commonly observed in patients affected by 
cystic leukodystrophies after trauma or febrile 
episodes, all conditions known to perturb 
brain homeostasis ([201] and reference 
therein, [202,203]). This body of evidence 
suggests that in disorders caused by a primary 
astrocyte defect environmental factors 
perturbing CNS homeostasis can modify the 
clinical course of the disease independently 
of the type of mutation, thus hampering 
genotype-phenotype correlations.
An interesting hypothesis is that brain 
damage in genetic leukodystrophies could 
be the result of failure of some astrocyte-
mediated regulatory pathways influencing 
glial cell homeostatic control during brain 
development [204]. Further investigations 
on the pathogenesis of astrocyte-mediated 
leukodystrophies and the availability of new 
disease models are needed to elucidate 
whether gene-environmental interactions 
during development are modulated at the 
astrocyte level and how genetic defects in 
astrocytes can affect CNS developmental 
processes.
Concluding remarks and 
perspectives 
During the past 20 years it has become clear 
that astrocytes exert complex and essential 
functions in the healthy CNS including 
regulation of synaptic transmission and 
information processing by neuronal circuits. 
Recently, unexpected roles of astrocytes in 
higher brain functions such as learning and 
memory, sleep behaviour and regulation of 
breathing, have been described [205-207]. 
Figure 9.  MRI of a 14 year old girl with 2 heterocompound  mutations in eIF2Be. (A) Notice the diffuse hypointensity 
of the abnormal signal in FLAIR weighted image sparing the U fibers indicating abnormal vacuolation of 
the white matter; (B) the same areas appear markedly hyperintense in the T2 weighted images and also 
involve the internal capsule; (C) the abnormal hyperintense T2 weighted signal also involves the white 
matter of the cerebellum; (D) the increased vacuolation is also clear in the parasaggital  FLAIR weighted 





The speculative concept that astrocytes 
contribute to the pathogenesis of 
neurodegenerative diseases is turning into 
reality as strong evidence proves astrocyte 
involvement in Alzheimer’s disease, 
amyotrophic lateral sclerosis, Huntington’s 
disease, cerebral edema and stroke, as a 
consequence of either loss or gain of astrocyte 
function [7,208]. However, it is also clear 
that these disorders arise from a complex 
combination of abnormalities in neurons, glial 
cells and immune system cells that we are only 
beginning to understand. The identification of 
the genetic defect and the elucidation of the 
pathogenetic mechanism underlying AxD and 
other cystic leukodystrophies, has opened a 
new avenue for understanding the impact that 
specific astrocyte functional impairment has on 
myelin and neuron degeneration. Advancing 
knowledge in this field may have significant 
implications for the development of therapeutic 
strategies for these rare leukodystrophies and 
other common CNS diseases. The majority of 
drugs currently used for brain diseases target 
neuronal proteins like receptors, channels 
or transporters. Therapeutic strategies may 
benefit by a stronger focus on the homeostatic 
control functions of astrocytes. Although 
some complex aspects of astrocyte physiology 
must be taken into account, such as regional 
differences in astrocyte phenotypes indicating 
that these cells represent a heterogeneous 
cell population [209,210], astrocytes are 
emerging as new potential pharmacological 
targets for CNS diseases [211]. The dissection 
of the molecular mechanisms of astrocyte 
reactivity is allowing identification of specific 
molecules whose function can be blocked or 
stimulated for therapeutic purposes [212,214]. 
The development of new technologies allows 
generating glial cells, including astrocytes, 
from embryonic stem cells or from the 
reprogrammed induced pluripotent stem cells 
(iPSCs) derived from skin fibroblasts [215-217]. 
These advancements have paved the way for 
the generation of easily accessible human 
cellular models to study astrocyte role in CNS 
development and the pathological mechanisms 
of astrocyte-mediated diseases [218,219]. 
These technologies are also providing new 
opportunities for regenerative therapies 
involving transplantation of astrocytes or glial 
progenitor cells [219,220-225]. Transplanted 
progenitor cells differentiating into astrocytes 
were reported to improve disease outcome 
in a mouse model of amyotrophic lateral 
sclerosis characterized by abnormal astrocytes 
overexpressing mutant superoxide dismutase 
(SOD), thus demonstrating the feasibility 
and efficacy of transplantation-based 
astrocyte replacement for this disease [225]. 
Transplantation of astrocytes genetically 
engineered to produce therapeutic molecules 
is another strategy under investigation 
[221,223]. Recently, cortical human astrocytes 
have been dedifferentiated into cells with 
a neural stem/progenitor cell phenotype, 
indicating that restoration of multipotency 
from human astrocytes can be exploited 
for the reprogramming of endogenous CNS 
cells in neurological disorders [226]. A better 
knowledge of astrocyte contribution to genetic 
leukodystrophies will help develop astrocyte-
based therapeutic strategies for these rare 
pathologies and for other neurological diseases.
Acknowledgments
We apologize to those authors whose original work 
could not be referenced due to space limitations. 
This work has been supported by Telethon (grant 
n. GGP11188B) and ELA Foundation (grant n. 2009-
002C5). AL is the recipient of an ELA foundation 
fellowship (grant n. 2012-021F2). 
References
[1] Virchow R., Cellular pathology as based upon physiological and 
pathological histology, translated from German by Chance B., 1859, 
2nd ed., reproduced by Dover Publications, New York, 1971, 356-382
[2] Golgi C., Sulla struttura della sostanza grigia del cervello 
(comunicazione preventiva),  Gazzetta Medica Italiana, Lombardia, 
1873, 33, 244-246
[3] Golgi C., Opera omnia, Hoepli, Milano, 1903
[4] Ramon Y., Cajal S., Histologie du systeme nerveux de l’homme et des 
vertebres, Maloine, Paris, 1909
[5] Peters A., Palay S.L., Webster H.F., The fine structure of the 
nervous system: the neurons and supporting cells, W.B. Saunders, 
Philadelphia, 1976, 232-248
[6] Bignami A., Stoolmiller A.C., Astroglia-specific protein (GFA) in clonal cell 
lines derived from the G26 mouse glioma, Brain Res., 1979, 163, 353-357
[7] De Keyser J., Mostert J.P., Koch M.W. J., Dysfunctional astrocytes as 
key players in the pathogenesis of central nervous system disorders, 
Neurol. Sci., 2008, 267, 3-16
[8] Powell E.M., Geller H.M., Dissection of astrocyte-mediated cues in 
neuronal guidance and process extension, Glia, 1999, 26, 73-83
[9] Zaheer A., Zhong W., Uc E.Y., Moser D.R., Lim R., Expression of mRNAs 
of multiple growth factors and receptors by astrocytes and glioma 
cells: detection with reverse transcription-polymerase chain reaction, 
Cell. Mol. Neurobiol., 1995, 15, 221-37
[10] Ullian E.M., Sapperstein S.K., Christopherson K.S., Barres B.A., Control 
of synapse number by glia, Science, 2001, 291, 657-661
[11] Christopherson K.S., Ullian E.M., Stokes C.C., Mullowney C.E., Hell 
J.W., Agah A., et al., Thrombospondins are astrocyte-secreted 
proteins that promote CNS synaptogenesis, Cell, 2005, 120, 421-
433
[12] Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., 
Nouri N., et al., The classical complement cascade mediates CNS 
synapse elimination, Cell, 2007, 131, 1164-1178
[13] Allaman I., Belanger M., Magistretti P.J., Astrocyte-neuron 
metabolic relationships: for better and worse, Trends Neurosci., 
2011, 34, 75-87
[14] Bushong E.A., Martone M.E., Jones Y.Z., Ellisman M.H., Protoplasmic 
astrocytes in CA1 stratum radiatum occupy separate anatomical 
domains, J. Neurosci., 2002, 22, 183-192
Translational Neuroscience
158
[15] Halassa M.M., Fellin T., Takano H., Dong J.H., Haydon P.G., Synaptic 
islands defined by the territory of a single astrocyte, J. Neurosci., 
2007, 27, 6473-6477
[16] Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl 
R.W., et al., Knockout of glutamate transporters reveals a major role 
for astroglial transport in excitotoxicity and clearance of glutamate, 
Neuron, 1996, 16, 675-686
[17] Rauen T., Taylor W.R., Kuhlbrodt K., Wiessner M., High-affinity 
glutamate transporters in the rat retina: a major role of the glial 
glutamate transporter GLAST-1 in transmitter clearance, Cell Tissue 
Res., 1998, 291, 19-31
[18] Verkhratsky A., Kirchhoff F., NMDA receptors in glia, Neuroscientist, 
2007, 13, 28-37
[19] Bak L.K., Schousboe A., Waagepetersen H.S., The glutamate/GABA-
glutamine cycle: aspects of transport, neurotransmitter homeostasis 
and ammonia transfer, J. Neurochem., 2006, 98, 641-53
[20] McKenna M.C., The glutamate-glutamine cycle is not stoichiometric: 
fates of glutamate in brain, J. Neurosci. Res., 2007, 85, 3347-3358
[21] Kimelberg H.K., Receptors on astrocytes - what possible functions?, 
Neurochem. Int., 1995, 26, 27-40
[22] Perea G., Navarrete M., Araque A., Tripartite synapses: astrocytes 
process and control synaptic information, Trends Neurosci., 2009, 32, 
421-431
[23] Shigetomi E., Bowser D.N., Sofroniew M.V., Khakh B.S., Two forms 
of astrocyte calcium excitability have distinct effects on NMDA 
receptor-mediated slow inward currents in pyramidal neurons, J. 
Neurosci., 2008, 28, 6659-6663
[24] Haydon P.G., Carmignoto G., Astrocyte control of synaptic 
transmission and neurovascular coupling, Physiol. Rev., 2006, 
86,1009-1031
[25] Zorec R., Araque A., Carmignoto G., Haydon P.G., Verkhratsky A., 
Parpura V., Astroglial excitability and gliotransmission: an appraisal 
of Ca2+ as a signalling route, ASN Neuro., 2012, 4, e00080
[26] Malarkey E.B., Parpura V., Mechanisms of glutamate release from 
astrocytes, Neurochem. Int., 2008, 52, 142-1454
[27] Evanko D.S., Zhang Q., Zorec R., Haydon P.G., Defining pathways of 
loss and secretion of chemical messengers from astrocytes, Glia, 
2004, 47, 233-240
[28] Garcia-Segura L.M., Melcangi R.C., Steroids and glial cell function, 
Glia, 2006, 54,485-498
[29] Stellwagen D., Malenka R.C., Synaptic scaling mediated by glial TNF-
alpha, Nature, 2006, 440, 1054-1059
[30] Abi-Saab W.M., Maggs D.G., Jones T., Jacob R., Srihari V., Thompson J., 
et al., Striking differences in glucose and lactate levels between brain 
extracellular fluid and plasma in conscious human subjects: effects of 
hyperglycemia and hypoglycemia, J. Cereb. Blood Flow Metab., 2002, 
22, 271-279
[31] Turner D.A., Adamson D.C., Neuronal-astrocyte metabolic interactions: 
understanding the transition into abnormal astrocytoma metabolism, 
J. Neuropathol. Exp. Neurol., 2011, 70, 167-176
[32] Pellerin L., Magistretti P.J., Sweet sixteen for ANLS, J. Cereb. Blood 
Flow. Metab., 2012, 32, 1152-1166
[33] Bélanger M., Allaman I., Magistretti P.J., Brain energy metabolism: 
focus on astrocyte-neuron metabolic cooperation, Cell Metab., 2011, 
14, 724-738
[34] Dienel G.A., Brain lactate metabolism: the discoveries and the 
controversies, J. Cereb. Blood Flow Metab., 2012, 32, 1107-1138
[35] Brown A.M., Baltan Tekkok S., Ransom B.R., Energy transfer from 
astrocytes to axons: the role of CNS glycogen, Neurochem. Int., 2004, 
45, 529-536
[36] Tsacopoulos M., Magistretti P.J., Metabolic coupling between glia and 
neurons, J. Neurosci., 1996, 16, 877-885
[37] Amaral A.I., Effects of hypoglycaemia on neuronal metabolism in the 
adult brain: role of alternative substrates to glucose, J. Inherit. Metab. 
Dis., 2012, [Epub ahead of print] doi: 10.1007/s10545-012-9553-3
[38] Magistretti P.J., Pellerin L., Cellular bases of brain energy metabolism 
and their relevance to functional brain imaging: evidence for a 
prominent role of astrocytes, Cereb.Cortex., 1996, 6, 50-61
[39] Kimelberg H.K., Nedergaard M., Functions of astrocytes and their 
potential as therapeutic targets, Neurotherapeutics, 2010, 7, 338-353
[40] Sofroniew M.V., Vinters H.V., Astrocytes: biology and pathology, Acta 
Neuropathol., 2010, 119, 7-35
[41] Gardner-Medwin A.R., Analysis of potassium dynamics in mammalian 
brain tissue, J. Physiol., 1983, 335, 393-426
[42] Walz W., Role of astrocytes in the clearance of excess extracellular 
potassium, Neurochem. Int., 2000, 36, 291-300
[43] Kofuji P., Newman E.A., Potassium buffering in the central nervous 
system, Neuroscience, 2004, 129, 1045-1056
[44] Djukic B., Casper K.B., Philpot B.D., Chin L.S., McCarthy K.D., Conditional 
knock-out of Kir4.1 leads to glial membrane depolarization, 
inhibition of potassium and glutamate uptake, and enhanced short-
term synaptic potentiation, J. Neurosci., 2007, 27, 11354-1165
[45] Butt A.M., Kalsi A., Inwardly rectifying potassium channels (Kir) in 
central nervous system glia: a special role for Kir4.1 in glial functions, 
J. Cell. Mol. Med., 2006, 10, 33-44
[46] D’Ambrosio R., Gordon D.S., Winn H.R., Differential role of KIR channel 
and Na(+)/K(+)-pump in the regulation of extracellular K(+) in rat 
hippocampus, J. Neurophysiol., 2002, 87, 87-102
[47] Wang D.D., Bordey A., The astrocyte odyssey, Prog. Neurobiol., 2008, 
86, 342-367
[48] Amzica F., Massimini M., Glial and neuronal interactions during slow 
wave and paroxysmal activities in the neocortex, Cereb. Cortex., 
2002, 12, 1101-1113
[49] Peters A., Palay S.L., Webster H.D., The fine structure of the nervous 
system, 3rd ed., Oxford University Press, New York, 1991
[50] Abbott N.J., Ronnback L., Hansson E., Astrocyte-endothelial 
interactions at the blood-brain barrier, Nat. Rev. Neurosci., 2006, 7, 
41-53
[51] Pellerin L., Magistretti P.J., Neuroenergetics: calling upon astrocytes 
to satisfy hungry neurons, Neuroscientist, 2004, 10, 53-62
[52] Connors N.C., Adams M.E., Froehner S.C., Kofuji P., The potassium 
channel Kir4.1 associates with the dystrophin-glycoprotein 




[53] Dalloz C., Sarig R., Fort P., Yaffe D., Bordais A., Pannicke T., et al., 
Targeted inactivation of dystrophin gene product Dp71: phenotypic 
impact in mouse retina, Hum. Mol. Genet., 2003, 12, 1543-54
[54] Amiry-Moghaddam M., Ottersen O.P., The molecular basis of water 
transport in the brain, Nat. Rev. Neurosci., 2003, 4, 991-1001
[55] Benfenati V., Amiry-Moghaddam M., Caprini M., Mylonakou 
M.N., Rapisarda C., Ottersen O.P., et al., Expression and functional 
characterization of transient receptor potential vanilloid-related 
channel 4 (TRPV4) in rat cortical astrocytes, Neuroscience, 2007,  148, 
876-892
[56] Ridder M.C., Boor I., Lodder J.C., Postma N.L., Capdevila-Nortes X., 
Duarri A., et al., Megalencephalic leucoencephalopathy with cysts: 
defect in chloride currents and cell volume regulation, Brain, 2011, 
134, 3342-3354
[57] Ernest N.J., Weaver A.K., Van Duyn L.B., Sontheimer H.W., Relative 
contribution of chloride channels and transporters to regulatory 
volume decrease in human glioma cells, Am. J. Physiol. Cell. Physiol., 
2005, 288, C1451-C1460 
[58] Teijido O., Martínez A., Pusch M., Zorzano A., Soriano E., Del Río J.A., et 
al., Localization and functional analyses of the MLC1 protein involved 
in megalencephalic leukoencephalopathy with subcortical cysts, 
Hum. Mol. Genet., 2004, 13, 2581-2594
[59] Walz W., Chloride/anion channels in glial cell membranes, Glia, 2002, 
40, 1-10
[60] Hayashi Y., Nomura M., Yamagishi S., Harada S., Yamashita J., 
Yamamoto H., Induction of various blood-brain barrier properties 
in non-neural endothelial cells by close apposition to co-cultured 
astrocytes, Glia, 1997, 19, 13-26
[61] Nico B., Ribatti D., Morphofunctional aspects of the blood-brain 
barrier, Curr. Drug Metab., 2012, 13, 50-60
[62] Mi H., Haeberle H., Barres B.A., Induction of astrocyte differentiation 
by endothelial cells, J. Neurosci., 2001, 21, 1538-1547
[63] Iadecola C., Nedergaard M., Glial regulation of the cerebral 
microvasculature, Nat. Neurosci., 2007, 10, 1369-1376
[64] Koehler R.C., Roman R.J., Harder D.R., Astrocytes and the regulation of 
cerebral blood flow, Trends Neurosci., 2009, 32, 160-169
[65] Schummers J., Yu H., Sur M., Tuned responses of astrocytes and their 
influence on hemodynamic signals in the visual cortex, Science, 
2008, 320, 1638-1643
[66] Petzold G.C., Murthy V.N., Role of astrocytes in neurovascular 
coupling, Neuron, 2011, 71, 782-97
[67] Carmignoto G., Gómez-Gonzalo M., The contribution of astrocyte 
signalling to neurovascular coupling, Brain Res. Rev., 2010, 63, 138-48
[68] Yeager M., Harris A.L., Gap junction channel structure in the early 21st 
century: facts and fantasies, Curr. Opin. Cell. Biol., 2007, 19, 521-528
[69] Theis M., Giaume C., Connexin-based intercellular communication 
and astrocyte heterogeneity. Brain Res., 2012, 1487, 88-98
[70] Dere E, Zlomuzica A., The role of gap junctions in the brain in health 
and disease, Neurosci. Biobehav. Rev., 2012, 36, 206-217
[71] Volterra A., Meldolesi J., Astrocytes, from brain glue to communication 
elements: the revolution continues, Nat. Rev. Neurosci., 2005, 6, 626-640
[72] Scemes E., Giaume C., Astrocyte calcium waves: what they are and 
what they do, Glia, 2006, 54, 716-725
[73] Charles A., Teaching resources. Glial intercellular waves, Sci. STKE, 
2005, 290, tr19
[74] Bernardinelli Y., Magistretti P.J., Chatton J.Y., Astrocytes generate 
Na+-mediated metabolic waves, Proc. Natl. Acad. Sci. USA, 2004, 101, 
14937-14942
[75] Parpura V., Verkhratsky A., Homeostatic function of astrocytes: Ca(2+) 
and Na(+) signaling, Transl. Neurosci., 2012, 3, 334-344
[76] Dreyfus C.F., Dai X., Lercher L.D., Racey B.R., Friedman W.J., Black 
I.B., Expression of neurotrophins in the adult spinal cord in vivo, J. 
Neurosci. Res., 1999, 56, 1-7
[77] Schwartz J.P., Taniwaki T., Messing A., Brenner M., Somatostatin 
as a trophic factor. Analysis of transgenic mice overexpressing 
somatostatin in astrocytes, Ann. N.Y. Acad. Sci., 1996, 22, 29-35
[78] Bögler O., Wren D., Barnett S.C., Land H., Noble M., Cooperation 
between two growth factors promotes extended self-renewal and 
inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) 
progenitor cells, Proc. Natl. Acad. Sci. USA, 1990, 87, 6368-63672
[79] Noble M., Murray K., Stroobant P., Waterfield M.D., Riddle P., Platelet-
derived growth factor promotes division and motility and inhibits 
premature differentiation of the oligodendrocyte/type-2 astrocyte 
progenitor cell, Nature, 1988, 333, 560-562
[80] Richardson W.D., Pringle N., Mosley M.J., Westermark B., Dubois-Dalcq 
M., A role for platelet-derived growth factor in normal gliogenesis in 
the central nervous system, Cell, 1988, 53, 309-319
[81] Barres B.A., Schmid R., Sendnter M., Raff M.C., Multiple extracellular 
signals are required for long-term oligodendrocyte survival, 
Development, 1993, 118, 283-295
[82] Sendtner M., Kreutzberg G.W., Thoenen H., Ciliary neurotrophic 
factor prevents the degeneration of motor neurons after axotomy, 
Nature, 1990,  345, 440-441
[83] Chernausek S.D., Insulin-like growth factor-I (IGF-I) production by 
astroglial cells: regulation and importance for epidermal growth 
factor-induced cell replication, J. Neurosci. Res., 1993, 34, 189-197
[84] Barnett S.C., Linington C., Myelination: Do Astrocytes Play a 
Role?, Neuroscientist, 2012, http://nro.sagepub.com/content/
early/2012/11/05/1073858412465655
[85] Blakemore W.F., Crang A.J., The relationship between type-
1 astrocytes, Schwann cells and oligodendrocytes following 
transplantation of glial cell cultures into demyelinating lesions in the 
adult rat spinal cord, J. Neurocytol., 1989, 18, 519-528
[86] Franklin R.J., Crang A.J., Blakemore W.F., Transplanted type-1 astrocytes 
facilitate repair of demyelinating lesions by host oligodendrocytes in 
adult rat spinal cord, J. Neurocytol., 1991, 20, 420-430
[87] Sorensen A., Moffat K., Thomson C., Barnett S.C., Astrocytes, but not 
olfactory ensheathing cells or Schwann cells, promote myelination of 
CNS axons in vitro, Glia, 2008, 56, 750-63
[88] Nash B., Thomson C.E., Linington C., Arthur A.T., McClure J.D., McBride 




[89] Ishibashi T., Dakin K.A., Stevens B., Lee P.R., Kozlov S.V., Stewart C.L., 
et al., Astrocytes promote myelination in response to electrical 
impulses, Neuron, 2006, 49, 823-932
[90] Kleopa K.A., Orthmann-Murphy J., Sargiannidou I., Gap junction 
disorders of myelinating cells, Rev. Neurosci., 2010, 21, 397-419
[91] Tress O., Maglione M., Zlomuzica A., May D., Dicke N., Degen J., et 
al., Pathologic and phenotypic alterations in a mouse expressing a 
connexin47 missense mutation that causes Pelizaeus-Merzbacher-
like disease in humans, PLoS Genet., 2011, 7, e1002146
[92] Lutz S.E., Zhao Y., Gulinello M., Lee S.C., Raine C.S., Brosnan C.F., 
Deletion of astrocyte connexins 43 and 30 leads to a dysmyelinating 
phenotype and hippocampal CA1 vacuolation, J. Neurosci., 2009, 
29, 7743-7752
[93] Verkhratsky A., Olabarria M., Noristani H.N., Yeh C.Y., Rodriguez J.J., 
Astrocytes in Alzheimer’s disease, Neurotherapeutics, 2010, 7, 399-412
[94] Coulter D.A., Eid T., Astrocytic regulation of glutamate homeostasis 
in epilepsy, Glia, 2012, 60, 1215-1226
[95] Rothstein J.D.,Current hypotheses for the underlying biology of 
amyotrophic lateral sclerosis, Ann. Neurol., 2009, 65 Suppl 1, S3-S9
[96] Faideau M., Kim J., Cormier K., Gilmore R., Welch M., Auregan G., 
et al., In vivo expression of polyglutamine-expanded huntingtin 
by mouse striatal astrocytes impairs glutamate transport: a 
correlation with Huntington’s disease subjects, Hum. Mol. Genet., 
2010, 19, 3053-3067 
[97] Simpson J.E., Ince P.G., Lace G., Forster G., Shaw P.J., Matthews F., et 
al., Astrocyte phenotype in relation to Alzheimer-type pathology 
in the ageing brain, Neurobiol. Aging, 2010, 31, 578-590
[98] Wang Y., Qin Z.H., Molecular and cellular mechanisms of excitotoxic 
neuronal death, Apoptosis, 2010, 15, 1382-1402
[99] Carmignoto G., Haydon, P.G., Astrocyte calcium signaling and 
epilepsy, Glia, 2012, 60, 1227-1233
[100] Schroder W., Seifert G., Huttmann K., Hinterkeuser S., Steinhauser 
C., AMPA receptor-mediated modulation of inward rectifier K+ 
channels in astrocytes of mouse hippocampus, Mol. Cell. Neurosci., 
2002, 19, 447-458
[101] D’Ambrosio R., Maris D.O., Grady M.S., Winn H.R., Janigro D., 
Impaired K(+) homeostasis and altered electrophysiological 
properties of post-traumatic hippocampal glia, Neurosci., 1999, 
19, 8152-8162
[102] Capendeguy O., Horisberger J.D., Functional effects of Na+,K+-
ATPase gene mutations linked to familial hemiplegic migraine, 
Neuromolecular. Med., 2004, 6, 105-116
[103] Sicca F., Imbrici P., D’Adamo M.C., Moro F., Bonatti F., Brovedani 
P., et al., Autism with seizures and intellectual disability: possible 
causative role of gain-of-function of the inwardly-rectifying K+ 
channel Kir4.1, Neurobiol. Dis., 2011, 43, 239-247
[104] Nico B., Ribatti D., Role of aquaporins in cell migration and edema 
formation in human brain tumors, Exp. Cell. Res., 2011, 317, 2391-
2396
[105] Benga O., Huber V.J., Brain water channel proteins in health and 
disease. Mol. Aspects Med., 2012, 33, 562-578
[106] Liu J.P., Tang Y., Zhou S., Toh B.H., McLean C., Li H., Cholesterol 
involvement in the pathogenesis of neurodegenerative diseases, 
Mol. Cell. Neurosci., 2010, 43, 33-42
[107] Chen G., Li H.M., Chen Y.R., Gu X.S., Duan S., Decreased estradiol 
release from astrocytes contributes to the neurodegeneration in a 
mouse model of Niemann-Pick disease type C, Glia, 2007, 55, 1509-
1518
[108] Kovács R., Heinemann U., Steinhäuser C., Mechanisms underlying 
blood-brain barrier dysfunction in brain pathology and 
epileptogenesis: role of astroglia, Epilepsia, 2012, 6, 53-59 
[109] Verkhratsky A., Parpura V., Recent advances in (patho)physiology of 
astroglia, Acta Pharmacol. Sin., 2010, 31, 1044-1054
[110] Arundine M., Tymianski M., Molecular mechanisms of calcium-
dependent neurodegeneration in excitotoxicity, Cell Calcium, 
2003, 34, 325-337
[111] Mirza B., Hadberg H., Thomsen P., Moos T., The absence of reactive 
astrocytosis is indicative of a unique inflammatory process in 
Parkinson’s disease, Neuroscience, 2000, 95, 425-432
[112] Zador Z., Stiver S., Wang V., Manley G.T., Role of aquaporin-4 in 
cerebral edema and stroke, Handb. Exp. Pharmacol., 2009, 190, 
159-170
[113] Sofroniew M.V., Molecular dissection of reactive astrogliosis and 
glial scar formation, Trends Neurosci., 2009, 32, 638-647
[114] Eddleston M., Mucke L., Molecular profile of reactive astrocytes-
implications for their role in neurological disease, Neuroscience, 
1993, 54, 15-36
[115] Argaw A.T., Asp L., Zhang J., Navrazhina K., Pham T., Mariani J.N., et 
al., Astrocyte-derived VEGF-A drives blood-brain barrier disruption 
in CNS inflammatory disease, J. Clin. Invest., 2012, 122, 2452-2468
[116] Colombo E., Cordiglieri C., Melli G., Newcombe J., Krumbholz M., 
Parada L.F., et al., Stimulation of the neurotrophin receptor TrkB on 
astrocytes drives nitric oxide production and neurodegeneration, 
J. Exp. Med., 2012, 209, 521-535
[117] Rossi D., Volterra A., Astrocytic dysfunction: insights on the role in 
neurodegeneration, Brain Res. Bull., 2009, 80, 224-232
[118] Hinson S.R., McKeon A., Lennon V.A., Neurological autoimmunity 
targeting aquaporin-4, Neuroscience, 2010, 168, 1009-1018
[119] Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger 
T., et al., Antibody to aquaporin-4 in the long-term course of 
neuromyelitis optica, Brain, 2008, 131, 3072-3080
[120] Ratelade J., Verkman A.S., Neuromyelitis optica: aquaporin-4 based 
pathogenesis mechanisms and new therapies, Int. J. Biochem. Cell. 
Biol., 2012, 44, 1519-1530
[121] Haj-Yasein N.N., Vindedal G.F., Eilert-Olsen M., Gundersen G.A., 
Skare Ø., Laake P., et al., Glial-conditional deletion of aquaporin-4 
(Aqp4) reduces blood-brain water uptake and confers barrier 
function on perivascular astrocyte endfeet, Proc. Natl. Acad. Sci. 
USA, 2011, 108, 17815-17820
[122] Masaki K., Suzuki S.O., Matsushita T., Yonekawa T., Matsuoka T., Isobe 
N., et al., Extensive loss of connexins in Baló’s disease: evidence 
for an auto-antibody-independent astrocytopathy via impaired 
Translational Neuroscience
161
astrocyte-oligodendrocyte/myelin interaction, Acta Neuropathol., 
2012, 123, 887-900
[123] Matsuoka T., Suzuki S.O., Iwaki T., Tabira T., Ordinario A.T., Kira J., 
Aquaporin-4 astrocytopathy in Baló’s disease, Acta Neuropathol., 
2010, 120, 651-660
[124] Hazell A.S., Astrocytes are a major target in thiamine deficiency and 
Wernicke’s encephalopathy, Neurochem. Int., 2009, 55, 129-135
[125] Hazell A.S., Rao K.V., Danbolt N.C., Pow D.V., Butterworth R.F., 
Selective down-regulation of the astrocyte glutamate transporters 
GLT-1 and GLAST within the medial thalamus in experimental 
Wernicke’s encephalopathy, J. Neurochem., 2001, 78, 560-568
[126] Hazell A.S., Sheedy D., Oanea R., Aghourian M., Sun S., Jung J.Y., 
et al., Loss of astrocytic glutamate transporters in Wernicke 
encephalopathy, Glia, 2010, 58, 148-156
[127] Hilgier W., Olson J.E., Brain ion and amino acid contents during 
edema development in hepatic encephalopathy, J. Neurochem., 
1994, 62, 197-204
[128] Schliess F., Görg B., Häussinger D., Pathogenetic interplay between 
osmotic and oxidative stress: the hepatic encephalopathy 
paradigm, Biol. Chem., 2006, 387, 1363-1370
[129] Butterworth R.F., Altered glial-neuronal crosstalk: cornerstone in 
the pathogenesis of hepatic encephalopathy, Neurochem. Int., 
2010, 57, 383-388
[130] Brenner M., Johnson A.B., Boespflug-Tanguy O., Rodriguez D., 
Goldman J.E., Messing A., Mutations in GFAP, encoding glial 
fibrillary acidic protein, are associated with Alexander disease, Nat. 
Genet., 2001, 27, 117–120
[131] Li R., Messing A., Goldman J.E., Brenner M., GFAP mutations in 
Alexander disease, Int. J. Dev. Neurosci., 2002, 20, 259-268
[132] Kohlschütter A., Eichler F., Childhood leukodystrophies: a clinical 
perspective, Expert Rev. Neurother., 2011, 11, 1485-1496
[133] Kohlschütter A., Bley A., Brockmann K., Gärtner J., Krägeloh-Mann 
I., Rolfs A., et al., Leukodystrophies and other genetic metabolic 
leukoencephalopathies in children and adults, Brain Dev., 2010, 
32, 82-89
[134] Di Rocco M., Biancheri R., Rossi A., Filocamo M., Tortori-Donati P., 
Genetic disorders affecting white matter in the pediatric age, Am. 
J. Med. Genet. B. Neuropsychiatr. Genet., 2004, 129B, 85-93
[135] Boespflug-Tanguy O., Labauge P., Fogli A., Vaurs-Barriere C., Genes 
involved in leukodystrophies: a glance at glial functions, Curr. 
Neurol. Neurosci. Rep., 2008, 8, 217-229
[136] Huyghe A., Horzinski L., Hénaut A., Gaillard M., Bertini E., Schiffmann 
R., et al., Developmental splicing deregulation in leukodystrophies 
related to EIF2B mutations, PLoS One, 2012, 7, e38264
[137] Messing A., Brenner M., Feany M.B., Nedergaard M., Goldman J.E., 
Alexander disease, J. Neurosci., 2012, 32, 5017-5023
[138] Bugiani M., Boor I., Powers J.M., Scheper G.C., van der Knaap M.S., 
Leukoencephalopathy with vanishing white matter: a review, J. 
Neuropathol. Exp. Neurol., 2010, 69, 987-996
[139] van der Knaap M.S., Scheper G.C., Megalencephalic 
Leukoencephalopathy with Subcortical Cysts, In: Pagon R.A., Bird 
T.D., Dolan C.R., Stephens K., Adam M.P. (Eds.) GeneReviews™ 
[Internet], Seattle (WA), University of Washington, Seattle; 1993-
2003 Aug 11 [updated 2011 Nov 03]
[140] Messing A., Goldman J.E., Alexander Disease, Elsevier, Amsterdam, 
2004
[141] Yoshida T., Nakagawa, M., Clinical aspects and pathology of 
Alexander disease, and morphological and functional alteration of 
astrocytes induced by GFAP mutation, Neuropathology, 2012, 32, 
440-446
[142] Salvi F., Aoki Y., Della Nave R., Vella A., Pastorelli F., Scaglione C., et 
al., Adult Alexander’s disease without leukoencephalopathy, Ann. 
Neurol., 2005, 58, 813-814
[143] Barkovich A.J., Messing A., Alexander disease: not just a 
leukodystrophy anymore, Neurology, 2006, 66, 468-469
[144]  van der Knaap M.S., Ramesh V., Schiffmann R., Blaser S., Kyllerman 
M., Gholkar A., et al., Alexander disease: ventricular garlands and 
abnormalities of the medulla and spinal cord, Neurology, 2006, 66, 
494-498
[145] Tanaka K.F., Takebayashi H., Yamazaki Y., Ono K., Naruse M., Iwasato 
T., et al., The murine model of Alexander disease: analysis of GFAP 
aggregate formation and its pathological significance, Glia, 2007, 
55, 617-631
[146]  van der Voorn J.P., Pouwels P.J.W., Salomons G.S., Barkhof F., van 
der Knaap M., Unraveling pathology in juvenile Alexander disease: 
serial quantitative MR imaging and spectroscopy of white matter, 
Neuroradiology, 2009, 51,  669–675 
[147] Iwaki T., Kume-Iwaki A., Liem R.K., Goldman J.E., Alpha B-crystallin is 
expressed in non-lenticular tissues and accumulates in Alexander’s 
disease brain, Cell, 1989, 57, 71-78
[148] Der Perng M., Su M., Wen S.F., Li R., Gibbon T., Prescott A.R., et 
al., The Alexander disease-causing glial fibrillary acidic protein 
mutant, R416W, accumulates into Rosenthal fibers by a pathway 
that involves filament aggregation and the association of alpha 
B-crystallin and HSP27, Am J. Hum. Genet., 2006, 79, 197-213
[149] Messing A., Head M.W., Galles K., Galbreath E.J., Goldman J.E., 
Brenner M., Fatal encephalopathy with astrocyte inclusions in 
GFAP transgenic mice, Am. J. Path., 1998, 152, 391-398
[150] Hagemann T.L., Gaeta S.A., Smith M.A., Johnson D.A., Johnson 
J.A., Messing A., Gene expression analysis in mice with elevated 
glial fibrillary acidic protein and Rosenthal fibers reveals a stress 
response followed by glial activation and neuronal dysfunction, 
Hum. Mol. Genet., 2005, 14, 2443-2458
[151] Tang G., Xu Z., Goldman J.E., Synergistic effects of the SAPK/JNK 
and the proteasome pathway on glial fibrillary acidic protein 
(GFAP) accumulation in Alexander disease, J. Biol. Chem., 2006, 
281, 38634-38643
[152] Tang G., Perng M.D., Wilk S., Quinlan R., Goldman J.E., Oligomers of 
mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome 
system in alexander disease astrocytes, and the small heat shock 




[153] Mignot C., Boespflug-Tanguy O., Gelot A., Dautigny A., Pham-Dinh 
D., Rodriguez D., Alexander disease: putative mechanisms of an 
astrocytic encephalopathy, Cell. Mol. Life Sci., 2004, 61, 369-385
[154] Hagemann T.L., Connor J.X., Messing A., Alexander disease-
associated glial fibrillary acidic protein mutations in mice induce 
Rosenthal fiber formation and a white matter stress response, J. 
Neurosci., 2006, 26, 11162-11173
[155] Hagemann T.L., Boelens W.C., Wawrousek E.F., Messing A., 
Suppression of GFAP toxicity by alphaB-crystallin in mouse models 
of Alexander disease, Hum. Mol. Genet., 2009, 18, 1190-1199
[156] Tian R., Wu X., Hagemann T.L., Sosunov A.A., Messing A., McKhann 
G.M., et al., Alexander disease mutant glial fibrillary acidic protein 
compromises glutamate transport in astrocytes, J. Neuropathol. 
Exp. Neurol., 2010, 69, 335-345
[157] Mignot C., Delarasse C., Escaich S., Della Gaspera B., Noé E., Colucci-
Guyon E., et al., Dynamics of mutated GFAP aggregates revealed by 
real-time imaging of an astrocyte model of Alexander disease, Exp. 
Cell. Res., 2007, 313, 2766-2779
[158] Tang G., Yue Z., Talloczy Z., Goldman J.E., Adaptive autophagy in 
Alexander disease-affected astrocytes, Autophagy, 2008, 4, 701-713
[159] Cho W., Messing A., Properties of astrocytes cultured from GFAP 
over-expressing and GFAP mutant mice, Exp. Cell. Res., 2009, 315, 
1260-1272
[160] Chen B., Moreland J., Zhang J., Human brain functional MRI and DTI 
visualization with virtual reality, Quant. Imaging Med. Surg., 2011, 
1, 11-16
[161] van der Knaap M.S., Barth P.G., Stroink H., Van Nieuwenhuizen O., 
Arts W.F., Hoogenraad F., et al., Leukoncephalopathy with swelling 
and a discrepantly mild clinical course in eight children, Ann. 
Neurol., 1995, 7, 324-334
[162] Singhal B.S., Gorospe J.R., Naidu S., Megalencephalic 
leukoencephalopathy with subcortical cysts, J. Child Neurol., 2003, 
18, 646-652
[163] Topku M., Saatci I., Topcuoglu M.A., Kose G., Kunak B., 
Megalencephaly and leukodystrophy with mild clinical course: a 
report on 12 new cases, Brain Dev., 1998, 20, 142-153
[164] Goutières F., Boulloche J., Bourgeois M., Aicardi J., 
Leukoencephalopathy, megalencephaly, and mild clinical course. 
A recently individualized familial leukodystrophy. Report on five 
new cases, J. Child Neurol., 1996, 11, 439-444
[165] Ben-Zeev B., Gross V., Kushnir T., Shalev R., Hoffman C., Shinar Y., 
et al., Vacuolating megalencephalic leukoencephalopathy in 12 
Israeli patients, J. Child. Neurol., 2001, 16, 93-99
[166] Riel-Romero R.M., Smith C.D., Pettigrew A.L., Megalencephalic 
leukoencephalopathy with subcortical cysts in two siblings owing 
to two novel mutations: case reports and review of the literature, J. 
Child. Neurol., 2005, 20, 230-234
[167] Bugiani M., Moroni I., Bizzi A., Nardocci N., Bettecken T., Gärtner 
J., et al., Consciousness disturbances in megalencephalic 
leukoencephalopathy with subcortical cysts, Neuropediatrics, 
2003, 34, 211-214
[168] Leegwater P.A., Yuan B.Q., Van Der Steen J., Mulders J., Konst A.A., 
Boor P.K., et al., Mutations of MLC1 (KIAA0027), encoding a putative 
membrane protein, cause megalencephalic leukoencephalopathy 
with subcortical cysts, Am. J. Hum. Genet., 2001, 68, 831-838
[169] Pascual-Castroviejo I., Viaño J., Pascual-Pascual S.I., Quiñones 
D., Congenital and evolving vascular disorders associated with 
cutaneous hemangiomas: case report, Neuropediatrics, 2009, 40, 
148-151
[170] Duarri A., de Heredia M.L., Capdevila-Nortes X., Ridder M.C., 
Montolio M., Lopez-Hernandez T., et al., Knockdown of MLC1 in 
primary astrocytes causes cell vacuolation: a MLC disease cell 
model, Neurobiol. Dis., 2011, 43, 228-238
[171] Leegwater P.A., Boor P.K., Yuan B.Q., van der Steen J., Visser A., Konst 
A.A., et al., Identification of novel mutations in MLC1 responsible 
for megalencephalic leukoencephalopathy with subcortical cysts, 
Hum. Genet., 2002, 110, 279-283
[172] Patrono C., Di Giacinto G., Eymard-Pierre E., Santorelli F.M., 
Rodriguez D., De Stefano N., et al., Genetic heterogeneity of 
megalencephalic leukoencephalopathy and subcortical cysts, 
Neurology, 2003, 61, 534-537
[173] Boor I.P.K., de Groot K., Mejaski-Bosnjak V., Brenner C., van der Knaap 
M.S., Scheper G.C., et al., Megalencephalic leukoencephalopathy 
with subcortical cysts: an update and extended mutation analysis 
of MLC1, Hum. Mutat., 2006, 27, 505-512
[174] Teijido O., Casaroli-Marano R., Kharkovets T., Aguado F., Zorzano A., 
Palacín M., et al., Expression patterns of MLC1 protein in the central 
and peripheral nervous systems, Neurobiol. Dis., 2007, 26, 532-545
[175] Boor P.K., de Groot K., Waisfisz Q., Kamphorst W., Oudejans C.B., 
Powers J.M., et al., MLC1 a novel protein in distal astroglial 
processes, J. Neuropathol. Exp. Neurol., 2005, 64, 412-419
[176] Schmitt A., Gofferje V., Weber M., Meyer J., Mössner R., Lesch K.P., 
The brain-specific protein MLC1 implicated in megalencephalic 
leukoencephalopathy with subcortical cysts is expressed in glial 
cells in the murine brain, Glia, 2003, 44, 283-295
[177] Ambrosini E., Serafini B., Lanciotti A., Tosini F., Scialpi F., Psaila R., et 
al., Biochemical characterization of MLC1 protein in astrocytes and 
its association with the dystrophin-glycoprotein complex, Mol. 
Cell. Neurosci., 2008, 37, 480-493
[178] López-Hernández T., Ridder M.C., Montolio M., Capdevila-Nortes X., 
Polder E., Sirisi S., et al., Mutant GlialCAM causes megalencephalic 
leukoencephalopathy with subcortical cysts, benign familial 
macrocephaly, and macrocephaly with retardation and autism, 
Am. J. Hum. Genet., 2011, 88, 422-432
[179] Jeworutzki E., López-Hernández T., Capdevila-Nortes X., Sirisi S., 
Bengtsson L., Montolio M., et al., GlialCAM, a protein defective in 
a leukodystrophy, serves as a CIC-2 Cl- channel auxiliary subunit, 
Neuron, 2012, 73, 951-961
[180] Duarri A., Teijido O., López-Hernández T., Scheper G.C., Barriere 
H., Boor I., et al., Molecular pathogenesis of megalencephalic 
leukoencephalopathy with subcortical cysts: mutations in MLC1 
cause folding defects, Hum. Mol. Genet., 2008, 17, 3728-3739
Translational Neuroscience
163
[181] Lanciotti A., Brignone M.S., Camerini S., Serafini B., Macchia G., 
Raggi C., et al., MLC1 trafficking and membrane expression in 
astrocytes: role of caveolin-1 and phosphorylation, Neurobiol. Dis., 
2010, 37, 581-595
[182] Brignone M.S., Lanciotti A., Macioce P., Macchia G., Gaetani M., Aloisi 
F., et al.,  The beta1 subunit of the Na, K-ATPase pump interacts 
with megalencephalic leucoencephalopathy with subcortical 
cysts protein 1 (MLC1) in brain astrocytes: new insights into MLC 
pathogenesis, Hum. Mol. Genet., 2011, 20, 90-103
[183] Lanciotti A., Brignone M.S., Molinari P., Visentin S., De Nuccio C., 
Macchia G., et al.,  Megalencephalic leukoencephalopathy with 
subcortical cysts protein 1 functionally cooperates with the TRPV4 
cation channel to activate the response of astrocytes to osmotic 
stress: dysregulation by pathological mutations, Hum. Mol. Genet., 
2012, 21, 2166-2180
[184] Benfenati V., Caprini M., Dovizio M., Mylonakou M.N., Ferroni S., 
Ottersen O.P., et al., An aquaporin-4/transient receptor potential 
vanilloid 4 (AQP4/TRPV4) complex is essential for cell-volume 
control in astrocytes, Proc. Natl. Acad. Sci. USA, 2011, 108, 2563-
2568
[185] Benfenati V., Amiry-Moghaddam M., Caprini M., Mylonakou M.N., 
Rapisarda C., Ottersen O.P., et al., Expression and functional 
characterization of transient receptor potential vanilloid-related 
channel 4 (TRPV4) in rat cortical astrocytes, Neuroscience, 2007, 
148, 876-892
[186] Bugiani M., Boor I., Powers J.M., Scheper G.C., van der Knaap M.S., 
Leukoencephalopathy with vanishing white matter: a review, J. 
Neuropathol. Exp. Neurol., 2010, 69, 987-996
[187] van der Knaap M.S., Leegwater P.A., Könst A.A., Visser A., Naidu 
S., Oudejans C.B., et al., Mutations in each of the five subunits of 
translation initiation factor eIF2B can cause leukoencephalopathy 
with vanishing white matter, Ann. Neurol., 2002, 51, 264-270
[188] Fogli A., Schiffmann R., Hugendubler L., Combes P., Bertini E., 
Rodriguez D., et al., Decreased guanine nucleotide exchange 
factor activity in eIF2B-mutated patients, Eur. J. Hum. Genet., 2004, 
12, 561-566
[189] van der Knaap M.S., Kamphorst W., Barth P.G., Kraaijeveld C.L., 
Gut E., Valk J., Phenotypic variation in leukoencephalopathy with 
vanishing white matter, Neurology, 1998, 51, 540-547
[190] Dietrich J., Lacagnina M., Gass D., Richfield E., Mayer-Pröschel M., 
Noble M., et al., EIF2B5 mutations compromise GFAP+ astrocyte 
generation in vanishing white matter leukodystrophy, Nat. Med., 
2005, 11, 277-283
[191] Wong K., Armstrong R.C., Gyure K.A., Morrison A.L., Rodriguez D., 
Matalon R., et al.,  Foamy cells with oligodendroglial phenotype 
in childhood ataxia with diffuse central nervous system 
hypomyelination syndrome, Acta Neuropathol., 2000, 100, 635-
646
[192] Rodriguez D., Gelot A., della Gaspera B., Robain O., Ponsot G., 
Sarlieve L.L., et al.,  Increased density of oligodendrocytes in 
childhood ataxia with diffuse central hypomyelination (CACH) 
syndrome: neuropathological and biochemical study of two cases, 
Acta Neuropathol., 1999, 97, 469-480
[193] Francalanci P., Eymard-Pierre E., Dionisi-Vici C., Boldrini R., Piemonte 
F., Virgili R., et al., Fatal infantile leukodystrophy: a severe variant of 
CACH/VWM syndrome, allelic to chromosome 3q27, Neurology, 
2001, 57, 265-270
[194] Bugiani M., Boor I., van Kollenburg B., Postma N., Polder E., van 
Berkel C., et al., Defective glial maturation in vanishing white 
matter disease, J. Neuropathol. Exp. Neurol., 2011, 70, 69-82
[195] Geva M., Cabilly Y., Assaf Y., Mindroul N., Marom L., Raini G., et 
al., A mouse model for eukaryotic translation initiation factor 
2B-leucodystrophy reveals abnormal development of brain white 
matter, Brain, 2010, 133, 2448-2461
[196] Kantor L., Pinchasi D., Mintz M., Hathout Y., Vanderver A., Elroy-Stein 
O., A point mutation in translation initiation factor 2B leads to a 
continuous hyper stress state in oligodendroglial-derived cells, 
PLoS One, 2008, 3, e3783
[197] van der Voorn J.P., van Kollenburg B., Bertrand G., Van Haren K., Scheper 
G.C., Powers J.M., et al., The unfolded protein response in vanishing 
white matter disease, J. Neuropathol. Exp. Neurol., 2005, 64, 770-775
[198] Huyghe A., Horzinski L., Hénaut A., Gaillard M., Bertini E., Schiffmann 
R., et al., Developmental splicing deregulation in leukodystrophies 
related to EIF2B mutations, PLoS One, 2012, 7, e38264
[199] Bugiani M., Postma N., Polder E., Dieleman N., Scheffer P.G., Sim 
F.J., et al., Hyaluronan accumulation and arrested oligodendrocyte 
progenitor maturation in vanishing white matter disease, Brain, 
2013, 136, 209-222
[200] Sloane J.A., Batt C., Ma Y., Harris Z.M., Trapp B., Vartanian T., 
Hyaluronan blocks oligodendrocyte progenitor maturation and 
remyelination through TLR2, Proc. Natl. Acad. Sci. USA, 2010, 107, 
11555-11560
[201] McAllister T.W., Neurobiological consequences of traumatic brain 
injury, Dialogues Clin. Neurosci., 2011, 13, 287-300
[202] Biddle C., The neurobiology of the human febrile response, AANA 
J., 2006, 74, 145-50
[203] Combes V., Guillemin G.J., Chan-Ling T., Hunt N.H., Grau G.E., The 
crossroads of neuroinflammation in infectious diseases: endothelial 
cells and astrocytes, Trends Parasitol., 2012, 28, 311-319
[204] Molofsky A.V., Krencik R., Ullian E.M., Tsai H.H., Deneen B., Richardson 
W.D., et al., Astrocytes and disease: a neurodevelopmental 
perspective, Genes Dev., 2012, 26, 891-907
[205] Gibbs M.E., Bowser D.N., Hutchinson D.S., Loiacono R.E., Summers 
R.J., Memory processing in the avian hippocampus involves 
interactions between beta-adrenoceptors, glutamate receptors, 
and metabolism, Neuropsychopharmacology, 2008, 33, 2831-2846
[206] Halassa M.M., Florian C., Fellin T., Munoz J.R., Lee S.Y., Abel T., et 
al., Astrocytic modulation of sleep homeostasis and cognitive 
consequences of sleep loss, Neuron, 2009, 61, 213-219
[207] Gourine A.V., Kasymov V., Marina N., Tang F., Figueiredo M.F., Lane 
S., et al., Astrocytes control breathing through pH-dependent 
release of ATP, Science, 2010, 329, 571-575
Translational Neuroscience
164
[208] Christensen R.K., Petersen A.V., Perrier J.F., How do glial cells 
contribute to motor control, Curr. Pharm. Des., 2013, [Epub ahead 
of print] doi: CPD-EPUB-20130121-5
[209] Verkhratsky A., Sofroniew M.V., Messing A., de Lanerolle N.C., 
Rempe D., Rodríguez J.J., et al., Neurological diseases as primary 
gliopathies: a reassessment of neurocentrism, ASN Neuro., 2012, 4, 
e00082
[210] Oberheim N.A., Goldman S.A., Nedergaard M., Heterogeneity of 
astrocytic form and function, Methods Mol. Biol., 2012, 814, 23-45
[211] Kimelberg H.K., Nedergaard M., Functions of astrocytes and their 
potential as therapeutic targets, Neurotherapeutics, 2010, 7, 338-353
[212] Jeong S.R., Kwon M.J., Lee H.G., Joe E.H., Lee J.H., Kim S.S., et al., 
Hepatocyte growth factor reduces astrocytic scar formation and 
promotes axonal growth beyond glial scars after spinal cord injury, 
Exp. Neurol., 2012, 233, 312-222
[213] Fontana A.C., de Oliveira Beleboni R., Wojewodzic M.W., Ferreira 
Dos Santos W., Coutinho-Netto J., Grutle N.J., et al., Enhancing 
glutamate transport: mechanism of action of Parawixin1, a 
neuroprotective compound from Parawixia bistriata spider venom, 
Mol. Pharmacol., 2007, 72, 1228-1237
[214] Escartin C., Bonvento G., Targeted activation of astrocytes: a potential 
neuroprotective strategy, Mol. Neurobiol., 2008, 38, 231-241
[215] Gupta K., Patani R., Baxter P., Serio A., Story D., Tsujita T., et al., 
Human embryonic stem cell derived astrocytes mediate non-cell-
autonomous neuroprotection through endogenous and drug-
induced mechanisms, Cell Death Differ., 2012, 19, 779-787
[216] Krencik R., Zhang S.C., Directed differentiation of functional 
astroglial subtypes from human pluripotent stem cells, Nat. 
Protoc., 2011, 6, 1710-1717
[217] Goldman S.A., Nedergaard M., Windrem M.S., Glial progenitor cell-
based treatment and modeling of neurological disease, Science, 
2012, 338, 491-495
[218] Juopperi T.A., Kim W.R., Chiang C.H., Yu H., Margolis R.L., Ross C.A., 
et al., Astrocytes generated from patient induced pluripotent stem 
cells recapitulate features of Huntington’s disease patient cells, 
Mol. Brain, 2012, 5, 17
[219] Noble M., Davies J.E., Mayer-Pröschel M., Pröschel C., Davies 
S.J., Precursor cell biology and the development of astrocyte 
transplantation therapies: lessons from spinal cord injury, 
Neurotherapeutics, 2011, 8, 677-693
[220] Davies S.J., Shih C.H., Noble M., Mayer-Proschel M., Davies J.E., 
Proschel C., Transplantation of specific human astrocytes promotes 
functional recovery after spinal cord injury, PLoS One, 2011, 6, 
e17328
[221] Lee H.J., Lim I.J., Park S.W., Ko Y.B., Kim S.U., Human neural stem 
cells genetically modified to express human nerve growth factor 
(NGF) gene restore cognition in mouse with ibotenic acid-induced 
cognitive dysfunction, Cell Transplant., 2012, 21, 2487-2496
[222] Jin Y., Neuhuber B., Singh A., Bouyer J., Lepore A., Bonner J., et 
al., Transplantation of human glial restricted progenitors and 
derived astrocytes into a contusion model of spinal cord injury, J. 
Neurotrauma, 2011, 28, 579-594
[223] Van Dycke A., Raedt R., Verstraete A., Theofilas P., Wadman W., Vonck 
K., et al., Astrocytes derived from fetal neural progenitor cells as a 
novel source for therapeutic adenosine delivery, Seizure, 2010, 19, 
390-396
[224] Hayashi K., Hashimoto M., Koda M., Naito A.T., Murata A., Okawa 
A., et al., Increase of sensitivity to mechanical stimulus after 
transplantation of murine induced pluripotent stem cell-derived 
astrocytes in a rat spinal cord injury model, J. Neurosurg. Spine, 
2011, 15, 582-593
[225] Lepore A.C., O’Donnell J., Kim A.S., Williams T., Tuteja A., Rao M.S., et 
al., Human glial-restricted progenitor transplantation into cervical 
spinal cord of the SOD1 mouse model of ALS, PLoS One, 2011, 6, 
e25968
[226] Corti S., Nizzardo M., Simone C., Falcone M., Donadoni C., Salani S., 
et al., Direct reprogramming of human astrocytes into neural stem 
cells and neurons, Exp. Cell. Res., 2012, 318, 1528-1541
Translational Neuroscience
